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CHAPTER 1 
MEASURING THE EFFECT OF TECHNOLOGICAL CHANGE IN 
HEALTH CARE COST AND EXPENDITURE 
 
1.1 Introduction  
Technological change is the engine of increasing efficiency, fueling economic 
growth, and achieving a higher level of well being for the masses. It is argued that 
virtually all of the economic growth that has occurred since the eighteenth century 
is ultimately attributable to innovation (Baumol, 2002). Health care is one of the 
most critical areas with tremendous impact and improvement resulting from the 
innovation. There is a remarkable improvement in human health evident from 
increased life expectancy and health related quality of life, all owing to improved 
knowledge and uses of new technologies that impact human health.  
A person born today has extraordinary possibilities and choices available in 
health care compared to one born fifty years or even twenty years ago. As a result, 
the consumption of health care has increased considerably in comparison with the 
past. It is reflected by the fact that health care consists of one of the largest shares 
of consumer expenditures in countries around the globe. Another part in the story of 
technological change is the price tag that is attached with the care. Along with 
spending, health care costs have increased tremendously in recent times. The 
increase in both cost and spending pose significant challenges to the performance 
and sustainability of a health care system.  
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Increased cost led to major concerns within the US health care system. 
Increased cost, for example, contributes to the pool of uninsurance, health care 
disparities, uncompensated care, and spillover effects to the general economy. In 
1991, Peter J. Neumann and Milton C. Weinstein stated that at that time American 
society was approaching, or might have reached, the point at which it was not 
possible to provide the best available health care to every American, regardless of 
cost (Neumann and Weinstein, 1991). They felt the de facto solution of the problem 
was to restrict access to health care for a segment of the population like the 
uninsured while preserving the myth of best available care for those fortunate 
enough to have coverage. Almost two decades later, the statement proves to be 
blatant and correct. Technology is considered as one of the underlying causes of ever 
increasing health care cost. 
Technological change can take place in different manners with different 
implications for spending and its growth. The most obvious change is to find a 
treatment that is not previously available. For example, if there is a new $10,000 
effective treatment for Alzheimer‟s disease, which currently has no treatment, then 
there would be instantly thousands of new patients nationwide who want that 
treatment. This would almost certainly lead to large increases in health care 
spending. However, in most circumstances, technological change and its impact on 
spending is less obvious and subtle than this example.  
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We can think of technological change in terms of a change in the content of 
the composition of inputs used to provide care. This will create four possible 
scenarios: 
Scenario I (No technological change): Same inputs are used over time. The 
cost of care depends upon how resource prices relatively change over time. 
Scenario II (Technological change): Same inputs are used but in different 
intensity and/or combination so that there is an improved outcome. 
Scenario III (Technological Change): New method of treatment is used 
comprising all or some of new inputs.  
Scenario IV (Technological Change): Learning by doing—higher level of 
perfection and efficiency achieved by practicing methods over and over.  
Whether a new technology actually increases cost or spending may depend 
upon other factors including whether the new technology adequately replaces 
existing treatment modalities and whether the new technology is more resource 
intensive. Further, the new technology may contribute to the rising costs of health 
care through each of the three distinct mechanisms: introduction, intensity of use 
and expansion (Gelijns and Rosenberg, 1994). Above all, rapid changes in health 
care technologies are facilitated by the technology friendly environment of the US 
health care system (Fuchs, 1996). There are plenty of incentives and minimal 
restrictions in the development, use and financing of new technologies in the US.  
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Technological change is widely accepted as a major driver of health care cost 
and expenditure in the US1 and elsewhere. Increase in health care expenditure is 
attributed to several factors including ageing, insurance coverage, income, 
availability of care, etc. Technological advancement, however, is the single most 
important factor to explain the growth of expenditure believed to be ranging from 
over 50% to over 75% of the total increase (Newhouse, 1992, Gelijns and Rosenberg, 
1994, and Fuchs, 1996). The main interest of this research is to quantify the 
association between technological change and increased spending over time.  
1.2 General Objectives and Aims 
The long term objective of this research is to seek an answer to the question: 
What is the share of technological change in the growth of health care cost and 
spending? This dissertation uses the case study of prostate cancer among the US 
elderly male population. In particular, this dissertation uses the information from 
cancer patients to measure the association between innovations in cancer care and 
associated change in spending in the period of 1990s and early 2000s. The research 
explores the question further to see how the health care spending of the people with 
cancer behaved over time given that there were some significant technological 
innovations and other subtle changes in care. The study hypothesize different 
                                               
1 In the US, the impact of technological change on health care spending and cost has become a 
national policy agenda. In 2003, a hearing was held before the Joint Economic Committee of the 
Congress on “Technology, Innovation, and Health Care Costs”. Similarly, the Congressional Budget 
Office (CBO) published a report, “Technological Change and Growth of Health Care Spending”, in 
2008.  
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scenarios in order to tease out the association between technological change and 
treatment cost over time.  
1.2.1 Specific Aims 
In the next three chapters, specific scenarios are presented with specific 
assumptions and focuses. The main ideas behind these scenarios and their specific 
aims are briefly described here.  
Part I: (Technology specific to cancer care—an overview) Imagine a scenario in 
which someone is diagnosed (DX) with condition X (cancer). How do pre- and 
post-diagnosis expenditure compare and behave over time? If post-DX 
expenditure grows faster, it will have important implications for 
technological change specific to X. As with DX comparison could be made 
about the treatment (RX), and specific treatments (SRX) and findings would 
give important implications about technological change in care associated 
with condition X. 
From the scenario presented in part I, we can address two important research 
questions. The first research question is: How did the short term health care 
expenditure grow over time for the patients who were diagnosed of prostate cancer 
relative to those who were undiagnosed (of prostate cancer)?  
Specific Aim 1: To calculate the historical trends of the short term health 
care expenditures to examine the differential growth of health care 
expenditures among patients who are diagnosed with prostate cancer 
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The second research question for this part is: How did the short term health care 
expenditure grow over time for the patients who were diagnosed and treated for 
prostate cancer relative to those who were diagnosed but untreated?  
Specific Aim 2: To calculate the historical trends of the short term health 
care expenditures to examine the differential growth of health care 
expenditures among patients who are treated for prostate cancer. 
Part II: (Productivity as an index of overall technology) It is difficult to calculate an 
objective measure of technological change. As the productivity of care has 
consistently changed over time, so has the health care spending. Using 
appropriate analytical techniques and assumptions, I measure the 
association between the overall technological change and spending using 
productivity as a proxy for technology.  
The research question associated with this part is: What is the association between 
overall change in health care technology and health care spending in cancer care?  
This amounts to finding the proportion of spending attributable to technological 
change in the area of general cancer care or treatment.   
Specific Aim 3: To construct and or use measures of overall technological 
change (technology index) in prostate cancer care and measure the 
association between technology index in prostate cancer care and short-term 
expenditures among people diagnosed with prostate cancer.   
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Part III: (Technology as one of the inputs of care) Suppose a new and better 
treatment   is introduced as a substitute for existing treatment     to treat 
a condition   . I estimate the incremental cost (IC) of    over    to see how 
IC behaves over time given that of     and     overlaps during that period. 
We can expect that trends for     and     have different intercepts, but what 
if they have different slopes? The slope is of specific interest and it has 
important implications.  
The research question for this part is whether innovations in cancer treatment fuel 
the growth of cost and spending over time.  
Specific aim 4: To evaluate the growth of short term incremental health 
care expenditures associated with recent innovations in external beam 
radiation therapy—three dimensional conformal radiation therapy (3D-CRT) 
and intensity modulated radiation therapy (IMRT)—to treat prostate cancer. 
The specific aims described here are associated with relevant hypotheses in 
respective chapters.  
1.1.2 Concepts and Terms 
In medicine, technological change includes a wide range of improvements 
including small changes such as increased frequency of a medication to major 
changes such as the plantation of an artificial organ. It is broadly defined to include 
any changes in clinical practice that enhance the ability of providers to diagnose, 
treat, or prevent health problems (CBO, 2008). Usually technological change 
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happens through gradual improvements and innovations on existing practices, 
techniques and treatments. The gradual and subtle nature of technological change 
poses empirical challenges to accurately define and measure the overall 
technological change and its aggregate effect on cost and spending.  
Technological change in medicine may be narrowly defined just to include the 
introduction and diffusion of major changes in methods to provide care. Such 
methods usually require a significant amount of new knowledge, investment in new 
capital and additional training of the workforce. The use of minimally invasive 
surgery instead of open surgery, methods for an early diagnosis of cancer or 
prescription medication to prevent cardiovascular events may come into this 
category. Major advances in health care may contribute to most of the increase in 
cost and spending. This study also uses the definition of technological change in a 
narrower sense as well.    
Here it is important to distinguish between the cost and spending. In order to 
define the cost, we must define the unit of output, which is tricky in health care. 
Health care has a multiplicity of attributes each with a certain value causing the 
same care worth more or less even if only one of the attributes changes. We need to 
factor out the quality in order to calculate the actual cost of health care. It is highly 
likely that the health care costs per quality adjusted unit may have actually become 
lower over time.  
In order to avoid intricacies, this research does not use cost in its usual 
meaning in economics.  Instead, it uses spending and cost equivalently as variables 
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of interest to measure the impact of technological change. Here in a broad sense, 
spending carries the concept of cost as well. For this purpose, health care is 
assumed to be a single commodity without factoring its characteristics that define 
its quality. If we assume that there is a single good or service named „care‟ then 
health care spending is simply the cost of getting that care. This study assumes that 
there is one good or service called „cancer care‟ and resultant spending is the cost of 
the care. The terms health care expenditure or health care spending are meant to 
be analogues.  
It is also very important to determine how to measure the cost and spending 
which are the major variables of interest in the study. The question is what is the 
best measure of the cost or spending? There are two candidates—charges and 
reimbursements. The study uses charges rather than reimbursements as a measure 
of expenditure for a number of reasons. First, it is assumed that the cost of new 
technologies, which essentially enters the cost as an input cost, is more directly 
reflected in the provider claims without any lag. On the other hand, Medicare 
reimbursements rates might be less sensitive to the true cost of new treatment than 
charges. Second, the information about the payment might be incomplete in the 
dataset because payments are made from different sources. Third, the main purpose 
of this study is to see the incremental cost of new treatments using differenced 
rather than absolute expenditure values. So, differencing and using control group 
will take care of much of the bias resulting from the use of charges.  
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The charges used to calculate cost or spending are not limited to one 
particular condition or a cause. The charges used to calculate spending include the 
charges made for receiving care for any cause or condition for periods specified.   
 
1.3 Significance of this study 
Since 1970, the US health care spending grew by 2.4 percentage points faster 
than the growth in the GDP rising from 7.2% of the GDP in 1970 to 16.2% in 2007. 
In the US, health care spending as a percentage of GDP is also significantly higher 
than that of other advanced countries (Kaiser Family Foundation, 2007).  The ever 
increasing health care spending presents an alarming picture of the future 
affordability and sustainability of the US health care system. It is estimated that a 
one-percentage-point gap between real per capita growth in health care 
expenditures and growth in GDP would be affordable2 through 2075, while a two-
percentage-point gap would only be affordable through 2039 (Chernew, Hirth and 
Cutler, 2003).  
The financial projection made by Medicare in year 2000 is that for next 75 
years the Medicare spending is going to grow by a percentage point higher than the 
growth of the GDP (Medicare, 2000). Unprecedented increase in health care 
spending puts a severe stress in public health care spending such as Medicare and 
Medicaid. The basic premise of such spending program is that government revenue 
is going to grow at the same rate wages and salaries grow. This eventually is going 
                                               
2 The affordability is measured in terms of the proportions of health spending in total spending. If 
health spending is equal of more than total spending it will be unaffordable.  
11 
 
 
to impose a restriction on the growth of public spending on healthcare. The check in 
expenditure growth over the real GDP is inevitable. However, the most critical 
question is when and how the check comes into effect.  
It is widely agreed that technological advancement is a major factor fueling 
the growth of health care cost and spending (For example, Newhouse (1992), Gelijns 
and Rosenberg (1994), etc). One consequence of the technological change is that 
resources are reallocated from non-health to health goods. The health care 
technology is ever improving and if so does spending and its share in GDP, then 
there will be a point when we will need to decide: how much technological 
improvements can the society bear? Suppose there is a Medicare-like transfer 
program featuring a tax rate that adjusts to ensure that the people are allowed to 
consume health care as much as technologically feasible; then a critical parameter 
of the model turns out to be the maximum transfer rate that society is willing to 
tolerate (Jones, 2002). From this point of view, the question of interest is what is 
the socially optimum level of care and optimum level of technological advancement?  
The outlook for future spending suggests that the effect of technology will 
remain as strong or get even stronger (Shactman et al. 2003; Strunk et al. 2006). 
The extent and nature of the relationship between technological advances in health 
care in the health care cost and spending is of a significant research interest with 
important implications for future health care policy making and reforms. In order to 
resolve the problems associated with growing health care cost and spending it is 
essential to understand the sources of such growth. As there is consensus about the 
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notion that technological change has the major role, there is relatively inadequate 
research and knowledge gap regarding the extent of such effect. Quantifying the 
effect of technology in percentage term would be an important contribution in this 
field.  
The next important question about the effect of technological change in 
health care is the nature of the relationship between the technology and spending. 
This particularly leads to the question of how the technology is linked to higher cost 
and spending. New technologies do not always enter cost or expenditure function in 
a straightforward way. There are producers, consumers and markets for 
innovations in health care like any other industries. However, the health care sector 
is significantly different from other sectors of the economy due to the existence of 
asymmetric information, role of health care provider in decision making and third 
party payments for consumption. The mechanisms by which technology affects cost 
and spending can vary by the nature of technologies. For example, the rate of 
diffusion of cost saving improvements is much slower than cost increasing 
innovations in some instances (Stagier et al. 2009). There is not a single way 
technologies affect cost and spending. A better understanding of the ways 
technological change affects cost and spending will be helpful in health technology 
assessment, cost effectiveness analysis, projection of future spending and 
formulation of technology policy.  
Understanding the role of technological progress in the growth of health care 
cost and spending is not only a matter of academic interest, but also an important 
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public policy interest now and in the future. Studies have found that countries with 
incentives to provide high tech procedures have experienced a relatively higher 
growth of those procedures suggesting that supply-side incentives determine high-
tech changes (McClellan and Kessler, 1999). There will be a scope for a technology 
policy if increased spending is not commensurate with improved outcomes.  
The significance of this study also is its focus on a major disease, cancer. 
Prostate cancer is the most prevalent cancer type among men. There has been 
substantial scientific focus on cancer care and treatment in recent times resulting in 
major advances in technologies and treatment innovations. Because cancer care is 
very expensive, it puts a significant pressure on health care financing including the 
public funding programs such as the Medicare. It is important to note that cancer 
primarily occurs in the senior populations aged 65 and older, the responsibility of 
Medicare.  
Technological change in health care and their impact on spending has a lot to 
do to determine the future sustainability of Medicare. A projection of future 
spending in cancer care using the future elderly model finds that no scenario of 
technological change holds a promise guaranteeing the financial future of the 
Medicare (Bhattacharya et al., 2005). This study will shed a light on this issue 
through the proper understanding of the dynamic relationship of technology and 
cost in cancer care.  
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1.4 Data 
This study uses the Surveillance, Epidemiology and End Results (SEER) 
Medicare-linked database which is created by linking two large population based 
sources of data. The data from Surveillance, Epidemiology and End Results (SEER) 
program of cancer registries is linked to data from Center for Medicare and 
Medicaid Services (CMS) of persons‟ Medicare claims for all covered services. The 
SEER part of data contains demographic, clinical and cause of death information for 
persons with cancer.  
The Medicare part of data contains information associated with all eligible 
claims for corresponding cancer cases from SEER data. The Medicare part also 
contains information on date of service, diagnosis, procedures, provider type, claims 
and payments, and inpatient stays covered under the Part A and B of the Medicare 
program. Within the Medicare data, there are inpatient, outpatient and carrier 
claims. Medicare inpatient claims include all Part A short stay, long stay, and 
skilled nursing facility by calendar year. The outpatient data contains all Part B 
claims from institutional outpatient providers including hospital outpatient 
departments and other clinics and facilities. Carrier claims, also known as National 
Claim History (NCH) records, includes all Part B claims from physicians and other 
non-institutional providers.  
The SEER database currently covers 26 percent of the US population by its 
16 registry sites across the United States. However, this study uses the data 
covered by 13 SEER locations as of year 2002.  
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From the main database, subsamples were created based on the design of the 
study and focus. The selection of cases including the selection criteria, structure of 
analytical datasets are explained in the respective chapters.  
1.5 Previous Literature 
In the literature, there is a general consensus that technological change in 
health care is the main source of rising cost and expenditure. Although empirical 
research in this field is relatively limited, there are some studies to examine the 
relationship between the technological change and health care spending in one way 
or another. Fuchs (1972) found that between 1947 and 1967, changing technology 
contributed 0.6 percentage points to the annual 8 percent growth in health care 
expenditure. Another study (Altman and Blendon, 1979) found 10 to 40 percent 
increase in expenditure over time owing to technological change in health care. 
Most studies have focused on specific aspect of the issue such as specific health 
condition or treatment.  
McClellan and Kessler (1999) did a global analysis of technological change in 
health care in the case of heart attacks. The study captures several aspects of 
technological changes in an international setting. One of the highlights from the 
findings of the study is that although many countries have lower levels of health 
care spending than the US but the growth rates of spending were very similar 
across the countries. It implies that the system factor determines the average level 
of health care spending in countries, while the technology determines its growth.   
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1.5.1 Technological change and its association with health care 
expenditure 
The health economics literature points to different ways technological change 
may lead to increased health care spending. Geligns and Rosenberg (1994) discuss 
three distinct mechanisms by which technological change in health care may cause 
an increase in the health care spending. The first of such mechanisms is the 
intensity of use of existing technologies. The intensity of use of a particular 
technology for a particular condition can vary across countries and regions. In the 
US, intensive practice is seen in high-technology medicine due to the technology 
imperative environment shaped by a complex set of financial, professional, social 
and institutional factors.  
Second, introduction of new or modified technologies provides a more subtle 
dynamics involved in technological change and associated health care expenditures. 
As new technologies are put in use, users provide their feedback to the developers. 
This feedback plays an important role in determining both the direction and rate of 
innovation efforts.  
The third mechanism according to Geligns and Rosenberg refers to the 
expanded applications of available technologies. The indications for which 
technologies are applicable can always expand for more indications. For example 
diagnostic devices such as CT scanners and MRI devices have vastly expanded uses 
over time thereby vastly increasing spending.    
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It is important to note that medical technologies are not inherently cost 
increasing. Availability of new health care technologies usually brings a puzzling 
effect that they reduce the cost per treatment while increasing the overall 
expenditures at the same time (Huckman and Cutler, 2004). The solution to the 
puzzle is found if we look at another effect of technological change i.e. increase in 
utilization. Whenever there is an increased use of existing technologies or there are 
new technologies to make previously untreatable conditions treatable or new 
innovations that make existing treatment more effective and safer, the utilization of 
such technology increases significantly, causing a substantial increase in 
expenditures.   
Another conundrum of the effect of technology is tied with presence of 
insurance. There are short-term and long-term effects of insurance tied with new 
technologies. The state of technology at a particular point of time determines the 
demand for insurance for that time. In short term, costly new technologies 
stimulate coverage, while improved coverage stimulates costs (Danzon and Pauly, 
2001). The long term effect of insurance comes from its impact on R&D spending 
and nature and character of medical practice (Finkelstein, 2006).  
Propensity to use a new technology is higher in the US as its healthcare 
system is friendlier to new technologies. The US health care system is built around 
a technologically friendly environment that inherently promotes newer technologies 
than elsewhere (Fuchs, 1986). The amount of resources going into the development 
of new technologies in part depends upon the future demand and financing for such 
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treatments. The long term impact of the interaction of R&D and insurance system 
is increase in health care expenditures (Weisbrod, 1991). The Wisbrod conjecture of 
impact of R&D, which is also a proxy for change in technology, on health 
expenditure is also supported by a study that uses the time series analysis of the 
long term relationship among aggregate real per capita health care expenditure, 
real GDP and total R&D spending in health sector. Data between 1960 and 1997 
support the strong and stable impact of technological progress in raising health care 
expenditures (Okunade and Murthy, 2002).  
The tendency to use new technologies is such that even the health 
management organization (HMO) system, which is effective in curtailing the cost of 
care in different ways, is ineffective to constrain the use of emerging medical 
technologies. A study in the case of gallbladder surgery shows no systematic 
difference between HMO and general population in the rate of growth of utilization 
of the new technology (Chernew, Fendrick, and Hirth, 1997). Evidence from the 
diffusion of MRI suggests that HMOs may be able to reduce health care costs 
related to latest technologies only by influencing the adoption of new medical 
equipment and technologies (Baker and Wheeler, 1998).  
In recent decades, increased R&D spending is devoted to the development of 
drugs that eventually lead to the increase of prescription drug spending. The 
introduction of successful new products through expensive R&D combined with an 
ageing population, third party prescription drug coverage, and better diagnostic 
techniques has swelled drug spending in the United States (Pammolli, and 
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Roccaboni, 2004; Berndt, 2004). Constant feeding of new technologies into the 
system can render any other approach of reducing cost ineffective. Aaron and 
Schwartz (1990) review the past efforts at reducing health outlays in the US and 
found that measures such as increased regulation and competition among providers 
has resulted in an one time saving. They conclude that if new technologies are 
introduced in an unchanged rate, the main underlying force that has driven up cost 
and spending would remain intact (Aaron and Schwartz, 1990).  
1.5.2 Technology and disease specific impact on health care 
expenditure 
There is increasing evidence that the availability of new and advanced 
technologies often causes an increased rate of utilization of procedures causing a 
significant rise in average spending. Technologies such as coronary artery bypass 
graft (CABG) required more capital and labor including the more expenses 
associated with spread of knowledge, compared to alternative treatment some 35 
years ago. Availability of technologies including CABG, imaging technologies, 
neonatal intensive care units, and radiation oncology facilities is associated with a 
greater per capita use and higher spending on these services (Bodenheimer, 2005). 
A disease level study by Cutler and McClellan (Cutler and McClellan, 2001) 
calculates the cost of technological change in four different conditions. The study 
finds substantial increase in cost due to technological advancement. For example, in 
heart attack patients, technological change accounted for more than 50% increase in 
the cost of treatment during the period from 1984 to 1998.  
20 
 
 
Several empirical studies relate availability of new technologies to increased 
utilization and higher health care expenditure. There are other studies that look 
into selected technologies. Baker et al. (2003) analyzed the relationship between the 
supply of new technologies and health care utilization and spending, focusing on 
some key technologies.  The study found a positive relationship between the 
availability of those technologies and amount of spending. A study (Cindy et al., 
1998) of the supply and use of five key medical services found that the growth in 
supply of medical technologies has exceeded the growth in utilization, which in turn 
has created excess capacity that can increase cost.  
A study of the relationship between magnetic resonance imaging supply and 
low back pain for Medicare patients by Baras and Baker (2009) found that increases 
in MRI supply are related to higher use of both low back MRI and surgery even 
though the usefulness of the procedures are not established. A study on countries 
under Organization for Economic Co-operation and Development (OECD) compared 
the number of specific health care facilities and per capita health care expenditures. 
It found that there is a positive relationship between the number of cardiac surgery 
facilities, cardiac catheterization laboratories, revascularisations, CT scanners, MRI 
machines and average health care expenditures across countries (OECD, 2003).      
 
1.6 Recent technological changes in prostate cancer care 
The current available treatment options for prostate cancer are based on the 
stage of cancer. Watchful waiting is treatment option for older patients especially 
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with low grade cancer presentation. Among the available treatment options, the 
most common are radical prostatectomy, external beam radiation therapy, implant 
radiation therapy and hormone therapy. Radical prostatectomy and radiation 
therapy are also known as definitive treatments while hormone therapy is mostly 
used as adjuvant or neo-adjuvant treatment. There are new type of treatments 
being tested in clinical trials including cryosurgery, chemotherapy, biologic therapy, 
high intensity focused ultrasound and proton beam radiation therapy(NCI, 2009 
web access).  
The most advanced form of therapies used today in prostate cancer treatment 
and care were developed in the 1980s and 1990s. The most notable events include 
the finding of prostate-specific antigen (PSA) as an indicator of prostate cancer 
(1980), use of Luteirizing (1981), nerve-sparing prostatectomy (1983), ultrasound 
guided implantation of radio-active seeds (1983), FDA approval of Leuprolide (1985) 
and PSA test (1986), ultrasound guided biopsy device (1988), FDA approval of 
Flutamide (1989), development of three dimensional conformal radiation therapy 
(1990), and FDA approval of PSA screening for the detection of early prostate 
cancer (1994) (Denmeade and Isaacs, 2002). Use of PSA screening as an early 
detection tool for prostate cancer led to a significant change in the care of prostate 
cancer. Cancers were detected at early stages and treated with higher intensity 
treatments like radical prostatectomy. This led to a decline in prostate cancer 
mortality first time in history and overall reduction of prostate cancer death rate 
related to prostate cancer screening is as much as 62 percent (Agalliu et al., 2007).   
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During the period for this study, no significantly new treatment was 
introduced other than innovations in the existing therapies. A recent innovation in 
surgical option for the prostate cancer treatment was minimally invasive radical 
prostatectomy (MIRP). Also known as laparoscopic radical prostatectomy, 
minimally invasive surgery involves the use of equipment with a small incision as 
opposed to large incisions in open form of radical prostatectomy. This technique 
gave rise to a new era of robotic prostatectomy as a major form of MIRP. From 2003 
to 2007, the number of MIRP procedures increased from one percent to more than 
40 percent of all prostatectomies (Hu et al, 2009).  
There have been significant changes in radiation therapies—both external 
and internal. In external beam radiation therapy (EBRT), the first and most notable 
change was the development of three dimensional conformal radiation therapy 
followed by intensity modulated radiation therapy. Three dimensional therapy 
replaced existing two dimensional dose planning system. The conformal therapy is 
based on an advanced imaging system that enables the precise targeting of cancer 
cells with larger radiation doses. The result is improved clinical effectiveness with 
less complication. The intensity modulated therapy which came into effect during 
late 90s is more advanced than three dimensional technique.  
In internal radiation therapy, which is known as brachytherapy, radioactive 
seeds are implanted in the cancerous tissues. These seeds produce radiation locally 
destroying the surrounding cells. The most recent and notable treatment 
innovations using brachytherapy are ultrasound guided transperineal permanent 
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brachytherapy of the prostate, and high dose rate brachytherapy. Internal beam 
radiation therapy is gaining increased popularity more recently with a projection 
that about one third of all localized prostate cancer patients will be choosing this 
option by the year 2005 (Thomadsen, 1999).  
Hormonal therapy, also known as the androgen deprivation therapy, is 
another widely used treatment option for prostate cancer patients. Unlike the 
surgery and radiation therapy, androgen deprivation therapy is used along with 
other therapies in adjuvant3 and neo-adjuvant settings. There was a substantial 
increase in the use of androgen ablation therapy both as primary treatment and 
adjuvant treatment between 1989 and 2001. A study finds that as a primary 
treatment, the treatment rate using androgen deprivation therapy was 48 percent 
among high risk groups in 2001. In the same year 75 percent of patients receiving 
radiation therapy were given androgen ablation as an adjuvant treatment 
(Cooperberg et al., 2003). The diffusion and utilization rate of androgen ablation 
treatment is growing faster than any other treatments for the condition.    
1.7 Basic Model 
Health care spending depends on several factors including the consumer 
preferences between health and non-health goods, prevalence of diseases, 
availability of care, health care policy, and system characteristics. At the individual 
level, the health care spending depends on the different set of factors within the 
                                               
3 Adjuvant therapy is given after the primary therapy and neo-adjuvant therapy is given before 
primary therapy.  
24 
 
 
given health care setting. The relationship between the individual spending and 
factors determining care can be summarized in the following functional form:  
                                       (1) 
where, EX denotes health care expenditure at individual level, X denotes individual 
characteristics including age, sex and insurance status, Y is provider 
characteristics, V is system characteristics, M is market features, T is level of 
technological advancement, and C is health care conditions including the incidence 
of diseases in the population.  
Consider simple estimation equation in the following form: 
                                   (2) 
where       is spending by individual i with condition or treatment j at time t and 
     is the unexplained residual. Following Newhouse (1992),      includes all the 
observed factors determining the demand for medical services that are included in 
equation (1) above other than technological change. Here technology is considered 
as residual—the part that is unexplained by all other factors is effect due to the 
variation of technology in health care.  
This approach to account for technological change is not without problems. 
Newhouse (1992) accepts that trying to attribute a residual to specific factor is an 
inherently frustrating exercise. However, he also believes that this is the best that 
can be done. Since the residual error term includes all the impact resulting from 
technological change, the next question is how to account for the growth rate of the 
residual.  
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The first thing in the accounting is to use a cross section estimate of β to 
estimate the residuals as                 . After the calculation of the residual, 
the next task is to determine what explains the residual change including how 
much of the residual is attributable to the new capabilities of medicine. Suppose we 
are able to observe the residual      for a number of years. Our interest then is to 
find its growth rate as: 
                                               (3) 
where,   denotes the growth rate of the residual, a measure of change in health care 
expenditure caused by technological changes. Taking logarithms on both sides 
                           
         
              
where, in the last equation      is a random error term,    is log of starting value of 
the residual and    is cumulative technology component. The last is an estimable 
equation by a regression technique.  
Equation (4) decomposes the residual term into three different components. 
The inherent assumption used in (4) is that technology changes in a continuous and 
smooth fashion. This assumption, however, is not realistic in health care spending. 
It is true that there are countless infinitesimal changes in medical practice every 
year contributing to both health care technology and spending. There are also some 
significant changes that may give a „shock effect‟ to the health outcome and cost. In 
(4) 
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this „shock‟ scenario, the technology component is decomposed into two different 
parts—steady and sporadic. For this scenario, equation (4) can be rewritten as 
                                                (5) 
here αt is a secular component that explains efficiency improvement that is common 
across the industry, such as the use of a certain diagnostic technique. The second 
term )( jShockf is the shock function that captures the effects of the introduction of a 
new technology that is specific to a certain condition. Equation (5) is a basic form of 
the model. There can be different ways to specify an estimation equation for model 
(5). Here is one of the full specifications of the equation (5) above. 
                                                          
   
 
   
      
                         (6) 
Here    is the treatment specific fixed effect and     and     capture the fixed effects 
and quadratic effects of the shocks respectively. We can introduce a time lapse term 
in the equation (6) above to capture the effect of the expansion of the shock or so 
called “intensity of use” of a certain treatment.  
 The model discussed above is very basic and it may not fit different situations 
that potentially exist. Most importantly, it is very challenging to empirically 
implement. First, the calculation of the residual that purely includes technology 
factor and random error is very difficult. It is because the residual may include 
many unobserved factors affecting expenditure, not only technology. It is 
empirically not feasible to include every possible factor that affects health care 
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spending in the estimation equation. Second, even if we can control for all factors 
affecting spending, they may not be independent of the technology factor. The 
independence of technological change is necessary in order to have an unbiased 
estimate of   in equation (2).  
 Even if the residual is decomposed from total expenditure, it is too strong to 
assume that technology is the only factor causing its growth. There can be other 
factors that are correlated with health care technology that might also affect 
spending. For example, like technology, there is an increase in obesity over time 
that also significantly affects health care spending. If the effect of increase in 
obesity is also included in the residual term, then the effect of technology will be 
highly overstated from the model above.    
 It is methodologically challenging to estimate the effect of technological 
change in health care expenditure. In this study, I have used different but 
empirically sound and proven methods to make some inferences about the effect of 
technological innovations in health care. Following this chapter, each chapter has 
the outline of the theoretical construct and empirical approach to calculate such an 
effect of technological changes.  
1.8 Chapter Summary and Conclusions 
Like all other parts of a modern economy, health care has changed 
tremendously over time due to technological advancement. However, the 
achievement has come with a huge price tag. The resulting growth of health care 
spending and cost has become a serious matter of concern.  
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 Previous literature in this area is relatively scarce. There are studies that go 
back as early as 1970s and 1980s that people began to worry about growing health 
care spending. This area of study received more focus during 1990s and onwards. 
Many studies link technology with growing health care cost in the US. It is widely 
agreed that technological advancement has a dominant role in ever increasing 
health care expenditures. Any effort now or in the future to manage or curtail 
health care cost has to deal with technological changes. There is an increasing scope 
for technology policy in that regard in order to make sure that the choices made in 
health technologies are efficient. It is also important to know the extent and nature 
of the relationship between technological change and health care spending. This 
research seeks to understand how new technologies affect health care expenditure 
and how much.  
 In order to meet the objectives of research, this study creates different 
scenarios to make inferences about the extent of the impact of technological 
changes. I use the case study of US elderly male population who are diagnosed with 
prostate cancer and who are available in SEER Medicare-linked database from 1991 
to 2002.  
 In the next three chapters, I use various study designs and techniques to 
quantify the relationship between health care spending and technological changes 
in the study population. These three chapters are independently designed and have 
no relationship with one another. The last chapter is devoted to summary and 
conclusion of the whole study.  
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CHAPTER 2 
HEALTH CARE EXPENDITURES: THE PICTURE IN LONG RUN 
 
2.1 Introduction 
Let us define growth picture as an overview of how health care costs related 
to prostate cancer (PCa) care have changed during the study period (1991-2002). 
The long run behavior of health care expenditure portrayed in a growth picture 
helps to understand the nature and direction of the growth. The growth picture also 
provides an overall view of how health care expenditure has changed in the long 
run. The main goal of this chapter is to obtain a growth picture of expenditures 
associated with prostate cancer care and derive implications for technological 
change in prostate cancer care.    
The growth in spending is not influenced by all factors in equal proportions. 
For example, the cost of an office visit of a physician may be relatively stable over 
time while the cost of an emergency room visit may have significantly changed. One 
of the strategies in deriving implications for technological change is to classify 
expenditures in different groups and categories, and do a comparative analysis of 
the growth in each expenditure group.  
Cancer care is given considerable attention in the United States. There has 
been considerable investment in finding a better cure or improving the quality of 
existing care. Every year, billions of dollars are spent in cancer related research 
from both public and private funding sources. The annual budget of National 
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Cancer Institute, a government funded program, alone reached above 5 billion 
dollars in the year 2010 (Kaiser, 2010). As a result of this there have been 
tremendous changes in cancer care in recent history including PCa care.  
The research questions addressed in this chapter are whether health 
spending associated with cancer care grew faster than average health care spending 
and how much of the additional contribution to health care cost came from 
technological advances in cancer care. This chapter focuses on finding a relative 
growth of cancer care spending resulting from changes in cancer care technologies 
compared with all other conditions. The finding from this analysis will give some 
idea whether there is a significantly different growth in spending for cancer care 
compared to the other medical conditions. The analysis is limited to cost or 
expenditure related to prostate cancer care.  
In accordance with the specific aim I and II of this research presented in 
Chapter 1, the study hypotheses for this chapter are stated here.  
Hypothesis I:   
H0.1: The growth trend in total health care expenditure in men diagnosed 
with PCa is the same as those without PCa in the study period.  
H1.1: The growth trend in total health care expenditure in men diagnosed 
with PCa is different from those without  PCa in the study period.  
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Hypothesis II:   
H0.2: The growth trend in total health care expenditure in men diagnosed 
with and treated for PCa is the same as those without PCa in the study 
period.  
H1.2: The growth trend in total health care expenditure in men diagnosed 
with and treated for PCa is different from those without PCa in the study 
period.  
Hypothesis III:   
H0.3: The growth trend in total health care expenditure in men treated for 
PCa with different methods is the same as those without PCa in the study 
period.  
H1.3: The growth trend in total health care expenditure in men treated for 
PCa with different methods is different from those without PCa in the study 
period.  
 
Each of the test variables in this analysis is a measure of historical health 
care expenditure on PCa at the individual level. Comparison of expenditures is 
made in terms of their trends. To this purpose, the first step is to calculate the cost 
associated with PCa care—its management and treatment.  
A quasi experimental design technique is used to calculate health care cost 
for cancer management or care. An analytical dataset was prepared by 
restructuring the data in a quasi experimental form. The SEER database contains 
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the population of all cancer patients living in various geographic locations of the 
US. The diagnosis of cancer is assumed to be a random event—unrelated to 
previous or potential spending of a patient. The cost of cancer management is 
simply the difference between pre-diagnosis and post diagnosis health care 
expenditure.  
The standard approach of calculating incidence cost of cancer is the 
incremental cost of cancer patients compared to matched non-cancer patients 
(Barlow, 2009). This is also known as the net cost of disease incidence. The 
technique of calculating net cost of cancer as the difference between cancer patient 
and similar non-cancer patient cannot account for the patient level or area level 
fixed effect. In this study, I have used a more rigorous approach that compares a 
random sample of cancer patients with non-cancer patients in terms of their both 
pre-diagnosis cost of care and post-diagnosis cost of care.  
2.2 Theoretical Construct 
In this section, I discuss some theoretical background to the empirical 
analysis of health care expenditure. What is the theoretical framework for the 
determination of health care spending? Studies that analyze health care 
expenditure usually lack an economic model that can justify the use of an empirical 
model. In the economic literature, there has not been much work on theoretical 
background of the health expenditure function. Here I am briefly describing the 
theoretical aspect of the expenditure function.  
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With different attributes, health care is one of the goods and services in the 
consumption basket of individuals. Health care has buyers and sellers in a market 
like setting, and price of health care is determined by the interaction between the 
buyers and sellers. For analytical simplicity, let us treat health care as a single good 
that can vastly vary in its features and attributes. The price of health care is then 
the total amount of spending made on health care during a particular period of 
time, say a year. Let us define a year of care as one unit of health care and the total 
spending made on one unit of care as the unit price of health care. The price of 
health care is not the same for every individual—it varies depending on the type 
and attributes of care one has received. Each person is essentially getting a 
different care—the same good but with different attributes. For example, sicker 
people receive vastly different health care than healthier people. Even one healthy 
person gets a slightly different care than other healthy persons.  
So health care is a single good with multiple attributes. The unit price of 
health care or total health care spending in a year therefore depends on the 
attributes of the care one receives. In economics, situations like this are modeled 
using the hedonic price model4. Let health care be   defined by a good with 
  measurable characteristics such that               and price 
                  is defined for each point in the vector space   .      is also 
known as a hedonic function.  
 Let us define a utility function for consumers as (Ekeland et al., 2002) 
                                               
4
 Here I am following Ekeland, Heckman and Nesheim, 2002 and 2004, and Nesheim, 2006 
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                (2-1) 
where,   represents preference parameters common across persons,   represents 
preference heterogeneity parameters that differ across people and          is 
consumption (where,   is unearned income).  
  The economic profits of suppliers that sell health care are defined as 
                    
 
 
                     (2-2) 
where,   represents common technology parameters,   represents a vector of 
technology parameters that differ across firms. It is assumed that          5 
and neither of the two are observable to the researcher.  
The first order conditions are: 
              , and 
                                         (2-3) 
The equilibrium is obtained by equalizing the demand and supply densities 
at each values of   and solving the linear differential equation. In normal linear and 
quadratic case the solution is quadratic in   (Ekeland, Heckman and Nesheim, 2002 
and 2004). The solution is written as: 
             
 
 
                    (2-4) 
where,   and    are parameters of interest. To determine   and   we need to 
utilize the equilibrium condition in the market. In market equilibrium, each firm 
chooses (       to maximize profits. The equilibrium hedonic prices      and 
                                               
5 Here dim means dimension of the vectors 
35 
 
 
characteristics   are determined by the distribution of buyers and their preferences, 
the cost and technology of firms and structure of the market (Nesheim, 2006).  
The ultimate goal of hedonic price models is to estimate both preference and 
technology parameters. This has become a tricky and controversial issue in the 
economics literature6. However, the main purpose of this discussion is to explore the 
theoretical underpinnings of a pricing function, and it is not intended to estimate 
the preference and technology parameters. By exploiting information from the 
equilibrium conditions, including product attributes, demand, supply and price we 
can estimate the pricing function above. We can write a marginal price function in 
terms of   and   as 
                           (2-5) 
Under certain assumptions this pricing function can be directly estimated by 
using regression techniques. Economic theory of hedonic price models does not put 
any restriction on the functional form of such equations. The functional forms of the 
price models are, therefore, arbitrarily chosen.  
 
2.3 Empirical Strategy 
The empirical analysis for this chapter is designed to identify the incremental 
effects of diagnosis of prostate cancer, treatment of prostate cancer, and the 
treatment of prostate cancer with specific treatments. A general form of estimation 
equation is given as 
                                               
6
 See Eakland, Heckman and Nesheim, 2004 for detail 
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                                                    (2-6) 
where    is a vector of time dummies. This model is also known as a price index 
model used to adjust for hedonic quality adjustment7. This version of the hedonic 
model will be the most suitable for the analysis in this chapter.  
There are different estimation methods available. Health care cost data 
demand special treatment from the analysts due to their idiosyncratic distribution. 
There are several studies on the cost that use different estimation strategies: (1) 
Ordinary Least Squares (OLS) regression in raw scale, (2) log-OLS regression, (3) 
Generalized linear models (GLMs) . The OLS based models with logged dependent 
variable are less precise than generalized linear models (GLM) for certain data 
generating processes (Manning and Mullahy, 2001). However, more recent 
literatures (Basu et al., 2005) suggest other estimators that appear to be more 
precise and suitable for the data generating processes in the health care costs. 
Below I briefly discuss the methods that I plan to use to estimate the regression 
models. 
 
2.3.1 Generalized Linear Model (GLM)  
Following Manning et al. (2005) the estimation of the regression models 
using maximum likelihood for a specific distribution—the generalized Gamma—
performs well against the alternative estimators. A simple health care cost 
regression model involves a response variable   as a function of vector   
                                               
7 For a detailed discussion of hedonic price adjustment model see Triplett (2004).  
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            of covariates for the mean function. The interest generally lies in one or 
more of    in the response function. If the response function is exponential, the 
conditional mean of the marginal effect can be denoted as: 
         
     
   
    
                             (2-8) 
Let            be independent measurements. Generalized linear models 
for independent data are characterized by a systematic component as featured in (1) 
and a random component following a probability distribution from an exponential 
family: binomial, Poisson, normal, Gamma and inverse Gaussian.  
For the generalized Gamma distribution, the expected value of   conditional 
on x is given by: 
                
 
 
               
 
  
   
 
 
          
 
  
               (2-9) 
An estimator for the marginal effect of a covariate    on the expected value of 
  is then given by: 
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            and 
     
    
 is a digamma function. When 
  is not modeled as a function of  , then the estimator for 
            
   
     (Manning et 
al., 2005).  
The maximum likelihood estimator of the parameter vector is obtained by 
solving the estimating equations 
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                                          (2-10) 
where,          , and  
  
  
  
 
 
 
 
 
 
   
   
 
   
   
   
   
   
 
   
    
 
 
 
 
 
 
The solution to the GLM estimating equations is asymptotically multivariate 
normal with mean equal to and covariance matrix 
             
 
2.3.2 Generalized Estimating Equations (GEE) 
Let     represent the jth measurement on the ith subject. There are 
   measurements on subject i and     
 
   total measurements. Correlated data are 
modeled as Generalized Estimating Equations (GEE) for estimating  . GEE is an 
extension of independence estimating equations (GLM) (5) using the same link 
function, linear predictor setup, variance function, and an additional covariance 
structure of the correlated components. The estimating equations can be written in 
the form 
                                          (2-11) 
where    
   
  
 . The solution to the GEE gives a consistent estimate of   that is 
asymptotically multivariate normal with covariance matrix  
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In the data, correlated measures are pre- and post-period individual 
expenditures and GEE is a suitable technique for the data.  
   
2.4 Empirical analysis 
2.4.1 Sample design 
Analytical samples of data were constructed for the purpose of this analysis. 
The overall study population included a fraction of the US population who were 
diagnosed with prostate cancer between 1991 and 2002. I have used the pre-cancer 
information of a group of patients serving as the comparison group for the analysis. 
So, the patients in comparison group were treated as if they never had cancer. For 
analytical purposes, the study population was put into four different categories.  
Category I (Population without cancer): This category was created from the study 
population from a random selection of individuals before they were diagnosed with 
cancer. The dataset contains the history of claims of all individuals from 1991 to 
2005 if they were enrolled in Medicare Part A and B during that period. Even 
though they were eventually diagnosed with prostate cancer, their selection was for 
their pre-diagnosis cancer free period. These cases were not included in any of the 
categories of cancer diagnosed patients described below. 
Category II (Population with cancer diagnosis): These cases, who serve as one of 
the treatment groups, were selected from the overall study population for their post 
diagnosis information. This includes all the people who are not in category I and 
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who have claim history of at least 320 days following the diagnosis of cancer. This 
category includes all PCa patients irrespective of their treatment status.  
Category III (Population diagnosed with and treated for cancer): This group 
includes a subset of category II individuals who are treated for prostate cancer with 
either radiation therapy or by radical prostatectomy within 4 months of the date of 
diagnosis. The use of 4 months period is due to two reasons. First, 4 months is a 
standard period within which most patients get a treatment intervention. Second, 
adequate follow-up time (in this case it is 8 months to one year) is required in order 
to capture all treatment related expenses. Category II cases serve as another 
treatment group for the analysis.  
Category IV (Population diagnosed with cancer and treated with radiation, surgery 
or neither method): This category includes Category III cases which are divided into 
three groups. Group 1 and 2 include those who received the treatment by surgery 
and by radiation respectively within 4 months of diagnosis.  Patients receiving both 
treatments were put in Group 1 because radiation therapy could be given as 
adjuvant or neo-adjuvant therapy. There is a third group which includes individuals 
who receive neither of the two treatments within 320 days following the date of 
diagnosis. The rationale for distinguishing patients by the type of treatment 
received is to differentiate them by their clinical characteristics. It is important to 
note that surgery and radiation are two definitive treatments for prostate cancer. 
Surgery is generally administered to healthier and younger patients with better 
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prognosis and initial stage of tumor growth. Patients receiving radiation therapy 
are more likely to be sicker, older and in more invasive stage of their cancer growth.  
 For each category an anchor date is created in order to define a pre-diagnosis 
period and post-diagnosis period and calculate total spending for each period for 
each category of individuals. The anchor date was the date 45 days prior to date of 
diagnosis for treatment group and 410 days prior to the date of diagnosis for 
comparison group. The use of 45 days before the date of diagnosis intended to 
capture all diagnosis related expenses regarded as a part of the total cancer care 
expenses. The pre diagnosis period is 365 days preceding the anchor date and post 
period consists of 365 days following the anchor date. Figure 2.1 (a and b) shows a 
sketch of sample selection timeline. 
 
 
 
 
 
 
Figure 2.1 (a) Timeline for treatment group 
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Figure 2.1 (b) Timeline for comparison group 
The sample selection process was predetermined. First, a random sample was 
generated with selection probability of 0.5. The selected sample and the rest of the 
cases are mutually exclusive. The sample is used as the reference group and the 
cases not included in the sample are used as treatment group.  
Total expenditures for each period for each case were calculated as the 
summation of all-cause8 health expenditures from inpatient, outpatient and 
physician claims. In order to ensure that all claims are included for each patient, 
full enrollment in the Medicare Part A and Part B was required for the post period 
for each patient. However, for the pre period, at least  180 days of enrollment was 
required. However, the expenditures of those having less than full enrollment in the 
pre period, were prorated for one year period using their available spending.  
Patients over age 85 or with end stage renal decease were removed from the sample 
in order to avoid outlying expenditures. Finally, all charges were adjusted for 2005 
prices using consumer price index. Here it is important to note that prescription 
                                               
8 All-cause health expenditure includes expenses made for all health care services, not only the 
expenses attributable to prostate cancer treatment  
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drug expenses or pharmacy claims are not included in the calculation of total 
expenditures.  
After applying all inclusion and exclusion criteria 97,125 cases were selected. 
The reference group has 49,976 cases, whereas the treatment group for category II 
has 47,149 cases.  
 
2.4.2 Identification 
The identification is based on the assumption that the diagnosis of cancer is 
randomly assigned irrespective of the past or potential future spending. The quasi 
experimental analytical sample design ensures the randomness. Further, the panel 
form of the data helps to minimize the bias arising from the patient characteristics, 
such as patient level fixed effects. For example, the selection of treatment may be 
based on the patients‟ potential spending, such as high cost patient having a 
systematically different treatment preferences.  
2.4.3 Sample Characteristics 
Table 2.1 shows patient characteristics in terms of key variables. The 
summary of sample characteristics is produced for the overall study population who 
satisfy the inclusion criteria. Those who are not eligible by the inclusion criteria are 
not included in the table. The classification is made broadly on the basis of 
diagnosis status. Diagnosed category is our treatment group, whereas undiagnosed 
category is our comparison group. Summary table is not produced for different 
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categories and groups mentioned above as it is expected that the distribution of 
patient population characteristics is not substantially different.  
Table 2.1 Sample characteristics by the status of diagnosis (DX) 
  Reference group 
N=49976 
Treatment group 
N=47149 
Variables Mean Std Mean Std 
Pre Expenditure $7,880 20506 $9,163 23311 
Post Expenditure $8,642 23054 $42,400 47273 
Distribution by year* (%) 
Dx in  1992 
  
1.59% 
   
0.01% 
 
Dx in  1993  9.36%   5.57%  
Dx in  1994  8.21%   8.48%  
Dx in  1995  7.56%   8.00%  
Dx in  1996  7.07%   7.58%  
Dx in  1997  7.23%   7.79%  
Dx in  1998  7.08%   7.28%  
Dx in  1999  7.52%   8.10%  
Dx in  2000  14.57%   15.54%  
Dx in  2001  14.85%   15.62%  
Dx in  2002  14.96%   16.02%  
Age in years 73.75 5.443 74.02 5.387 
Charlson Comorbidity score 2.24 2.013 2.25 2.016 
Race: African American 10% 0.298 10% 0.303 
Race: Other 7% 0.256 7% 0.256 
Metro 58% 0.493 58% 0.494 
Therapy Started n/a n/a 78% 0.413 
College education or higher by zip 
code 
28% 16.94 27.5% 16.88 
Mean income by zip code $50,400 21229 $50,163 21414 
*For reference group, anchor date was treated as the date of diagnosis for this 
purpose. 
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First two rows report the mean and standard deviation of pre- and post- 
period expenditures for the treatment and comparison groups. Presumably, the pre-
period mean expenditure should not be significantly different for treatment and 
control groups. However, they appear to be different. There is a valid reason for 
such a discrepancy. Remember that pre-diagnosis expenditure is one year newer in 
average for the treatment group. Even though they are discounted by using the CPI, 
the discounting is not sufficient to make them equal if medical price index rises 
faster than consumer price index.  
 No other variables included in the table are noticeably different except for the 
expenditure variables. The table also lists the distribution of treatment group by 
year of diagnosis. A larger proportion of the data falls towards the later part of the 
study period.   
  2.4.4 Analytical work 
 Finally, data analysis is carried out in order to estimate the associated 
spending or cost of the incidence of cancer. The cost associated with each of the 
categories II, III and IV are estimated vis-à-vis category I as explained above. In 
order to calculate the cost associated with diagnosis (category II), category II cases 
were pooled with category I cases. A dichotomous variable (DX=1|0) was created to 
indicate category II. The variable DX is the main variable of interest here.  
 Regression using GEE estimation technique was used for the analysis. Two 
types of estimations are made. First, regression estimation was used in order to 
adjust for the covariates and calculate trends of expenditures. Next, year specific 
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effects on cost or spending were estimated running a regression on the model (2-6) 
specified above.   
 
2.5 Findings 
2.5.1 Trends of expenditure by diagnosis status 
In this sub-section expenditures of cases in category II defined above are 
included. Figure 2.2 below shows how the short term incident cost of prostate cancer 
grew in the study period. The expenditures are plotted in both adjusted and 
unadjusted forms. The adjusted expenditures are found using regression method for 
age, race, incomes, geographic location and comorbidities. Using the estimates from 
regression models, expenditures are predicted for each observation. Then predicted 
expenditures are averaged by year of diagnosis and by treatment or reference group 
status.  
Unadjusted expenditures are calculated as follows. First, the difference of pre 
and post expenditures (differenced expenditure) for each individual in each of 
treatment and control group were calculated. Next the difference was averaged for 
each group and for each year. Finally, the net expenditure was calculated as the 
difference between annual average differenced expenditure of the control group and 
annual differenced expenditure for the treatment group.  
Figure 2.2 shows that spending associated with the diagnosis of cancer grew 
continuously throughout the period. The growth became sharp towards the end of 
the period. It is also evident that the expenditures, in 2005 dollar terms, more than 
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doubled during the study period. Note that the calculated expenditures are one year 
cost or spending associated with the diagnosis of prostate cancer irrespective of 
treatment status.  
 
Figure 2.2 Trends of net expenditure by diagnosis 
 
As shown by figure 2.2, the adjusted spending grew slightly faster than 
unadjusted spending and the gap between the two widened. This indicates that the 
distribution of covariates among cancer patients have changed over time.  
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Table 2.2: Estimates of cancer related spending by year of 
diagnosis 
 Estimates by diagnosis 
status 
(Dependent Variable = 
Expenditure) 
Estimates by diagnosis 
and treatment status 
(Dependent Variable = 
Expenditure) 
Year of 
diagnosis 
Coefficient 
(Std. Err) 
Marginal 
Effect 
Coefficient 
(Std. Err) 
Marginal 
Effect 
1992 0.740* (1.015) $12,301 0.54* (1.184) $8,960 
1993 1.343 (0.041) $31,137 1.59 (0.049) $48,018 
1994 1.398 (0.034) $33,179 1.66 (0.040) $51,658 
1995 1.415 (0.035) $33,995 1.64 (0.041) $51,040 
1996 1.504 (0.036) $38,161 1.71 (0.042) $55,188 
1997 1.578 (0.035) $41,862 1.77 (0.041) $59,018 
1998 1.676 (0.037) $47,282 1.85 (0.043) $65,625 
1999 1.762 (0.035) $52,228 1.93 (0.041) $71,184 
2000 1.755 (0.026) $50,209 1.90 (0.030) $67,027 
2001 1.880 (0.025) $57,945 2.00 (0.030) $74,770 
2002 2.002 (0.025) $66,434 2.12 (0.030) $85,267 
*Not significant at 5% level  
Note: Estimates of the coefficients on other control variables are not shown  
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The left half (first three columns) of Table 2.2 shows the estimated results for 
each year from the regression model (full equation estimates are shown in Appendix 
A). These are estimates of expenses for the year following diagnosis of the cancer 
patients who are diagnosed in the particular year. The regression equation included 
all covariates included in the data summary Table 2.1 except the therapy variable. 
The regression model also included a full set of place dummies for SEER registry 
locations. The estimation of coefficients and their implied values (the marginal 
effect) in dollar terms are also presented. For all years the estimates are significant 
even below the 1% level. The estimate for 1992 was insignificant. In 2005 dollar 
terms, people diagnosed with cancer (on average) spent about $66,000 more in 2002 
than the similar but cancer free population. This is up from $31,000 in 1993. The 
spending increment attributable to the diagnosis of cancer more than doubled 
during that period.  
2.5.2 Trends of expenditure by diagnosis and treatment status 
Most prostate cancer patients receive some sort of treatment within 4 months 
of diagnosis. Not everyone diagnosed with prostate cancer receives treatment 
immediately. Treatment decisions are based on the expected outcomes for the 
patient depending on several factors including patient‟s expected life, health 
condition, and stage of cancer. Those who do not receive treatment are kept under 
watchful waiting for any change in cancer behavior. It must be noted that those who 
do not receive a definitive treatment, either surgery or radiation therapy, may 
receive other less intensive treatment such as hormonal therapy. Hormonal therapy 
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given prior to a definitive treatment is called neo-adjuvant therapy. Those who have 
more advanced form of cancer may be given a palliative care that includes hormonal 
and other therapies.  
Presumably, patients not receiving a definitive therapy have lower spending. 
However, since our expenses include “all-cause” expenditures, this may create an 
illusory situation. People who do not receive treatment because of health and life 
expectancy reasons may have other significant expenses causing the overall 
expenditures to be high. But there might be some people who are otherwise healthy 
but do not receive an immediate treatment because their cancer is less threatening. 
Creating a sub-sample of individuals who do not receive a treatment leaves us with 
a more homogenous cohorts of people that will allow us to estimate the treatment 
expenses more precisely.  
The subsample used in this subsection includes all category III patients 
described above as treatment group. Those who do not receive any of the radiation 
or surgery treatments in the post-period are discarded. The reference group remains 
the same.  
The trends of net expenditures by diagnosis and treatment status are shown 
in Figure 2.3. Expenditures are relatively stable until 1995 and then they have 
sharper increase. Both adjusted and unadjusted expenditures have similar trends.  
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Figure 2.3 Trends of net expenditure by diagnosis and treatment status 
 
The right two columns of Table 2.2 show the estimated results of year effect. 
The estimated coefficients are highly significant except that for year 1992. The 
exponentiated linear prediction of the estimated values shows the marginal effect of 
the treatment group in dollar terms. Comparing the dollar expenditures of treated 
subsample with that of diagnosed subsample shows that the levels of expenditure 
for treated subsample is significantly higher than that of diagnosed albeit they have 
slower growth rate. From 1993 to 2002, the expenditure for treated group grew 
almost by 80 percent in 2005 dollar terms.  
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2.5.3 Trends by treatment types: 
For this section, category IV patients are used as treatment group, which are 
divided into three groups:  
Group I: Those who received surgery within 4 months of diagnosis 
Group II: Those who received radiation therapy within 4 months of diagnosis 
Group III: Those who received none of radiation therapy or surgery during 
the post period. This group is named as „no treatment‟ group.   
 
The trend of expenditure for each treatment type is estimated separately and 
their adjusted expenditures are presented in figure 2.4 below. Unlike the above two, 
the unadjusted expenditure trends are not shown for these groups. Also, the trends 
are plotted using Lowess plots which will smooth out the trends and allow an easy 
comparison.  
It is evident that the trend of expenditure of the radiation group is similar to 
that of „no treatment‟ group but with a higher intercept. The radiation group shows 
a slight fall in spending during the first half of the overall period, whereas no 
treatment group shows a moderate rise in the same period. Both radiation and no 
treatment group have relatively flat part in the middle of the study period. 
However, during the second half of the study period, spending for both of these two 
groups show a fairly noticeable and similar growing trend.  
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Figure 2.4 Lowess plots of expenditures by treatment type 
The expenditure trend of radical prostatectomy is very different. It grows 
continuously from the beginning to the end. This signifies substantial changes in 
surgery treatment as opposed to radiation or other treatment option.  
2.6 Discussion and conclusion 
The main purpose of this chapter is to get a general sense of how the 
expenditures associated with the prostate cancer behaved over time. Without 
pinpointing a particular aspect and doing a complex analysis, the database is 
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allowed to speak for itself. The observations made from the data are interesting and 
have important interpretations.   
Trends of expenditure were calculated and plotted in order to obtain a growth 
picture of health care spending for cancer care over the period. These trends 
provided a simple picture that is easily understandable just by eyeballing the 
trends. No special statistical tests were conducted to make inferences about the 
differences because the changes were fairly substantial and obvious.  
Results show that the health care spending for cancer care has increased 
substantially during the study period. People diagnosed with cancer have utilized 
health services at increasing rate over time implying the significant changes in the 
way cancer care is delivered. The care has become increasingly more resource 
intensive. Assuming that the prices of health care inputs used provide care for 
cancer patients did not change at different rate than the price of the rest of the 
inputs, this implies technological change in cancer care demands more resources.  
The results suggest that technological change specific to PCa alone contributes 
about 100 percent increase in health care spending in about 10 years‟ period. This 
also implies that technological advancement caused the PCa care expenditure to 
grow at the exponential rate of 7 percent each year during that period.  
The findings reject the hypothesis that people diagnosed with cancer do not 
have substantially different expenditure than those without cancer in the favor for 
the alternative hypothesis.  
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The trends of expenditures for diagnosed population and treated population 
also show some differences. The treated expenditures did not rise sharply during 
the early stage of study period. However, they have similar trend towards the end of 
the study period. The finding suggests that innovations in major treatment alone 
caused PCa care expenditure to grow by 80 percent. The hypothesis of no difference 
in expenditure between the diagnosed and treated group is rejected in the favor of 
alternative one.  
Comparison of expenditure growth by the method of treatment exemplifies 
the differences. Expenditures for surgery patients grew much faster over the entire 
period. Radiation group and no treatment group show only a moderate increase in 
spending during the second half of the study period. It implies significant changes 
in the treatment methods for those who receive surgery as their definitive 
treatment. This also suggests the changes in radiation treatment and other care 
after 1998. This again rejects the null hypothesis that the trends of expenditure for 
different methods of treatment are the same, in the favor of alternative one. Instead 
the alternative hypothesis that the growth trend in total health care expenditure in 
people treated for cancer with different methods is different from those without 
cancer in the study period has been accepted. 
Estimated cost can also be used to evaluate the population based cost-
effectiveness of technological advancement in PCa care. From 1993 to 2002, the 
average age of people dying of PCa increased from 78.81 years to 80.46 years in the SEER-
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Medicare population9. This is a gain of 1.65 life years in average.  Using the cost 
estimates, it implies that the cost for per life year gained is little more than 
$20,000. However, it is only the first year cost. Advances in prostate cancer care 
appear to be highly cost effective as costs for subsequent years are not substantial 
for most patients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                               
9 Calculated from the 1991-2002 SEER data.  
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CHAPTER 3 
USING A SINGLE MEASURE OF TECHNOLOGY 
 
3.1 Introduction 
In this chapter, I seek the answer to the question: What is the effect of overall 
technological change on overall healthcare spending? The specific aim of this 
chapter is to construct and use a measure of overall technological change in prostate 
cancer care and measure the association between the measure of technology and 
short-term incidence cost of prostate cancer.  In accordance with the specific aim III 
of this research presented in Chapter 1, the study hypothesis for this chapter is 
stated as follows.  
Hypothesis: For all individuals diagnosed with prostate cancer:  
H0.3: There is no significant association between technology index and total 
PCa care expenditure in the study period.   
H1.3: There is significant association between technology index and total 
PCa care expenditure in the study period. 
In order to be able to test this hypothesis, two key variables, technology and 
health care expenditure, are needed. This section, therefore, implicitly assumes that 
„technology‟ has some sort of measurement. In cross sectional terms, the amount of 
technology used to provide care to one person could differ from that of another 
person. If two persons are comparable in every other possible sense, the varying the 
amount of technology used to provide care may vary health outcome and therefore 
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health care expenditure between two persons. Here the outcome of interest is 
expenditure.  
How to construct a single measure of technology embodied with thousands of 
possible inputs that go in the care is a critical question. However, without a single 
measure of technology, it is impossible to find the answer to the research question 
for this chapter.  
Since constructing an objective measure of health care technology for a 
particular time is a difficult task, and therefore beyond the scope of this research, I 
used an alternative approach. The alternative is to look for any proxy that can most 
properly represent the measure of technology. This is based on an assumption that 
technological change always brings some improvement in outcomes. In other words, 
improvement in outcomes is „caused‟ by technological change. This means 
technological change is properly represented by the change in outcomes in the long 
run.  
My strategy is to use outcome as a proxy variable for technological change. 
There can be different outcomes as candidates for this purpose. One such measure 
can be provided by the survival rate following the diagnosis of prostate cancer. The 
survival rate can be used for a particular time frame, such as three year, five year 
or ten year survival rate following the diagnosis. The survival rate is a measure of 
how many people were alive within the time frame per 100 people diagnosed with 
that condition.  
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The second alternative is death rate owing to prostate cancer. Prostate cancer 
is still one of the leading causes of deaths among men in the US. The leading causes 
of death statistics, which measure how many of deaths per 100,000 population are 
attributed to various conditions, are available from secondary sources. Assuming 
constant incidence and prevalence rates, a falling prostate cancer death rate means 
that less people die of prostate cancer. But death is inevitable and everybody 
eventually dies of a certain „cause‟. A falling death rate caused by prostate cancer 
means more people are dying of other conditions. The cause of death is, therefore, 
only a relative measure of technological change which shows a relative progress in 
the cure and care of prostate cancer or cancer care in general.  
Both measures have their own limitations as measures of technological 
progress. Survival rate is highly sensitive to stage at diagnosis of cancer which is 
difficult to adjust. Due to increased usage of screening and health care awareness, 
more and more prostate cancers are detected in their early stage and early age of 
patients. This will affect the survival rate even without any change in the treatment 
and care of prostate cancer. The second measure, death rate owing to prostate 
cancer, as a proxy for technological change is a better alternative in this regard. 
There are limitations of death rates as a measure of outcome. One important 
limitation is that death information is obtained from death certificates, which do 
not accurately report the cause of death. However, I would argue in favor of this 
because it is more specific and measurable.  
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3.2 Theoretical Construct 
The primarily link between the technological change in health care and 
expenditure is given by the amount of resources that go into the care. In other 
words, technological change can lead to change in the types or amounts of inputs 
used to provide the care. Every technological change will need some change in 
inputs: either there are new inputs, more or less of existing inputs, a new mix of 
existing inputs, or a mix of new and existing inputs.   
A new technology is acceptable only when the net utility10 from it is at least 
as high as that from existing technology. This ensures that health outcomes are 
non-decreasing function of technological change. In other words, 
                          (1) 
for any technology    . Here   denotes a vector of inputs associated with the 
technology. Let   
 
 be an objective measure of technology for input mix  . Then 
above condition implies that   
    
 
. Let us also define a functional relationship 
between the input mixes and associated measure of technology as 
  
                      (2) 
However health utility is not directly observed. What we observe is health 
outcome. Let us assume that there is a direct mapping of health technology with 
health utility and the mapping is properly defined. In other words, health outcome 
directly varies with health technology given as: 
                                               
10 It may be defined as the marginal utility net of marginal cost of a new technology 
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                              (3)                               
where,   is a vector of parameters and,   is a vector of patient characteristics. 
Assuming the continuity of   , it further implies that  
      
  
 
          
   
   
  
   
where 
   
 
  
   and it implies that technology is a non-decreasing function of time.  
Similarly, health expenditure is a function of inputs that go into care.  
                  
         
                   (4) 
  
  
 
          
   
   
   
   
  
 
Again, 
   
 
  
   and 
         
   
   , but the sign of the derivative 
   
   
 is unknown. It 
implies that health expenditure can increase or decrease over time depending on 
the resource intensity of new technologies. Equations (3) and (4) provide the basic 
building blocks for the theoretical background for this chapter.  
3.3 Empirical Strategy  
The empirical problem of this chapter is to estimate the equation  
               ,                                          (5) 
and the main interest of this research is to measure 
  
   
. However, in order to make 
it estimable, we need to make some further assumptions. First, we need to make 
assumption about the functional form of the equation. Second, we need to use a 
proxy variable for   since the objective measure of   is not available.  
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The expenditure function is assumed to be non-linear with an additively 
separable assumption for the covariates on the right hand side. So the regression 
model for the expenditure equation is in the form  
                                          
 
     
                           (6) 
I use the outcome itself as a proxy for   for this purpose. Controlling for 
patient characteristics, health outcome      , gives the weighted measure of 
technological change.  
Here two strong assumptions are made: 
 Assumption 1 (Causality) 
An improvement in outcome must be due to a change in inputs or input mix 
which is broadly defined as technological change in health care. The reverse 
causality that more expenditure improves outcome is ruled out implying that  
outcome is not endogenous in the model.  
This assumption can be justified in health care setting where improving the 
outcome is of major concern for both patients and providers. There is a negligible 
marginal cost to patients for choosing the treatments that are safer and more 
effective. Because of third party payment, expected outcome rather than expected 
cost, plays the role while choosing a treatment. So the choice of treatment method is 
independent of expected expenditure. If a technologically more advanced option of 
treatment is chosen, it may be reflected in the outcome. The outcome even includes 
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the technological improvement through learning by doing. Therefore, outcome is a 
weighted measure of all improvements made in the care.  
Under the assumption of causality, a single equation non-linear regression 
technique with continuous outcome variable on the right hand side is used to 
measure the effect of technological change in cancer care expenditure. Generalized 
linear model (GLM) estimation technique11 is used in the analysis.  
The assumption of causality may seem too strong in this case. If the 
assumption fails, the estimation based on the assumption will be biased. In order to 
accommodate the possibility of endogeneity, the following assumption is made.     
Assumption 2 (Simultaneity) 
Expenditure and outcome are simultaneously determined.  So the outcome is 
endogenous in the expenditure model. This assumption allows for the 
possibility that expenditure has an impact on the outcome.  
As explained above, health outcome correctly reflects the use of technology 
which in turn determines the amount and type of inputs used. Expenditure depends 
on the amount and types of inputs used.  
 
 
 
 
 
                                               
11 This method is discussed in Chapter 2.  
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3.4 Empirical model  
I use simultaneous equation modeling12 to estimate the relationship. Let us 
assume that there are G endogenous variables in the system of equations. The     
equation for     of   individuals is written as  
       
        
                                                    (7) 
where,   is a vector of exogenous variables and   is a vector of       endogenous 
variables. Equation (5) is a structural form of   equation linear simultaneous 
equation model. The    vector of all exogenous variables   is assumed to satisfy  
                                                                         (8) 
The empirical strategy is to estimate equations (3) and (4) simultaneously treating 
the health outcome and expenditures variables as endogenous to the model.  
The structural parameters of the model can be consistently estimated if the 
rank and order conditions for identification are satisfied.  The order condition 
requires that the number of excluded exogenous variables from the equation must 
be at least as large as the number of included right-hand-side endogenous variables 
in the equation. This requirement, also known as the order condition with exclusion 
restrictions, is the necessary condition for identification.  
The rank condition of identification depends on linear restrictions and 
normalization restrictions on an endogenous variable. We need some background 
information before we can state the rank condition for identification. Let rewrite the 
system of linear equations (7) compactly as   
                                               
12 The theoretical model for this part is heavily drawn from Wooldridge (2002), Cameron and Trivedi 
(2006) and Green (2004).  
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                                                          (8)                               
where,   is a     vector of structural errors,   is a     matrix and   is   
 matrix.  
For all  equations of a structural model, we can solve it in terms of 
exogenous variables and obtain a reduced form equation as   
          
                                    (9)                             
where,        and       . The rearrangement is based on the assumption 
that the matrix   is non-singular and the variance matrix        is also non-
singular. Let    
 
 
  be the         matrix of structural parameters in equation 
(8). Let    be the         vector of structural parameters in the first equation 
(7). One element in the coefficient vector of endogenous variable in (7) is set to -1 as 
a normalization restriction so that there are         unknown elements in   . 
Assume that prior knowledge of    can be expressed as 
       
where,   is a         matrix of known constants   is the number of restriction on 
  .  
The rank condition requires that   is identified if and only if the rank 
condition              holds.  
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3.4 Empirical analysis 
     3.4.1 Sampling design and key variables 
The analytical sample used in this chapter includes all patients diagnosed 
with prostate cancer from 1991 to 2002. Only the patients who were continuously 
eligible for Part A and B of Medicare coverage were selected. The date prior to 45 
days of date of diagnosis was created for each case as an anchor date. Then 
aggregate expenditures were calculated for the period of 365 days from the anchor 
date. The aggregate expenditure includes all the claims for inpatient, outpatient 
and physician services.  
 Compared to the sample design of Chapter 2, the sample used in this chapter 
is different in a number of ways. First, this sample does not include comparison and 
treatment groups. Second, this sample does not include the expenditure of the 
previous period. Third, everyone in the sample has full expenditure information for 
one year. So no adjustment was needed for anyone having less than a full period‟s 
expenditure.  
Patients aged over age 85, or with end stage renal disease were removed from 
the sample in order to avoid outlying values of expenditure. Finally, all charges 
were adjusted for 2005 prices using the general consumer price index (CPI). 
    3.4.2 Identification 
As explained above, the identification is based on the rank and order 
conditions. The satisfaction of the rank condition is easy to see as the model has 
only two endogenous variables. To satisfy the order condition, I have used inclusion 
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and exclusion criteria in the equations. In the equation that determines health 
outcomes, I have used the year dummies in which the patient was diagnosed with 
cancer. It makes sense because the outcomes are clearly time-dependent, a patient 
diagnosed with cancer in 2002 is more likely to have better survival outcome than a 
patient diagnosed in 1991.  
Once we include the outcome variable in the expenditure equation, the year 
of diagnosis becomes purely redundant as all information is contained by the 
outcome variable. The assumption of this study is that outcome is the index of the 
technology of care that summarizes all the changes in the method of care brought by 
technological change. Therefore, we can exclude the time of diagnosis information 
from the expenditure equation.  
At least one variable which is in the expenditure equation needs to be 
excluded from outcome equation. I have excluded the variable that indicates 
whether patients were given one of the definitive therapies within 4 months of 
diagnosis. The therapy variable causes expenditure to increase but it is not 
assumed to have any relevance in the outcome equation. Conceptually, the outcome 
is the function of the overall level of technology of any time and the year of 
diagnosis fully incorporates that information.  So, the indicator for the definitive 
therapy is purely redundant in the outcome equation given the presence of 
diagnosis years.    
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3.4.3 Three Stage Least Square (3SLS) Approach 
 In simultaneous equation model (SEM), I use the three-stage least square 
(3SLS) approach to estimate the equations. Unlike the two-stage equation by 
equation estimation of the model, 3SLS assumes errors are homoskedastic but are 
correlated across equations in order to ensure consistency in the estimates.    
  3.4.4 Summary of key variables 
Table 3.1 (a and b) shows the summary statistics of the key variables 
included in the empirical estimation equations. The key variables also include death 
rates associated with prostate cancer in the year. Information of death rates is 
obtained from NCI database and other published reports. It is important to note 
that there is a significant lag between the outcome (death rate in this regard) and 
PCa care following the diagnosis. While patients receive care right from the date of 
diagnosis, the eventual survival or death from the disease occurs after several years 
in average. So the death rate in the year of diagnosis provides little information 
about the type of care these patients receive that affects their ultimate survival. For 
this reason, I have used outcome variables that are constructed by leading the 
outcome variable by one, two, three, four and five years following the diagnosis13. 
The death rate with five year lead means that outcomes after five years are more 
associated with the type of care the patients receive today right after they are 
diagnosed.  
                                               
13 For example a five year lead value means using the death rate of 2005 for the patients diagnosed 
in 2001.  
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Table 3.1 (a) shows the death rate due to prostate cancer by year with rates 
led by one, two, three, four and five years. It also shows the five year moving 
average rate. All the rates are in terms of every 100,000 population aged 65 or 
above. In 1991, the death rate was 291.08 while it decreased to 209.67 in 2002. In 
2006, which is five years after 2002, the rate was reduced to 173.56.  
Table 3.1 (a): Death rates owing to prostate cancer in every 100,000 male 
population aged 65 or above by year and their lead and moving average values 
 Year 1 Year 2 Year 3 Year 4 Year 5 Moving Average 
1991 291.08 290.58 292.48 286.48 277.23 287.57 
1992 290.58 292.48 286.48 277.23 267.61 282.88 
1993 292.48 286.48 277.23 267.61 254.26 275.61 
1994 286.48 277.23 267.61 254.26 242.49 265.61 
1995 277.23 267.61 254.26 242.49 235.48 255.41 
1996 267.61 254.26 242.49 235.48 226.13 245.19 
1997 254.26 242.49 235.48 226.13 217.38 235.15 
1998 242.49 235.48 226.13 217.38 209.67 226.23 
1999 235.48 226.13 217.38 209.67 197.00 217.13 
2000 226.13 217.38 209.67 197.00 189.20 207.88 
2001 217.38 209.67 197.00 189.20 182.92 199.23 
2002 209.67 197.00 189.20 182.92 173.56 190.47 
Average 257.57 249.73 241.28 232.15 222.74 240.69 
Std. Dev. 30.72 33.29 34.81 34.53 33.76 33.26 
 
Including the average death rate during five years following the year of 
diagnosis makes six outcome variables. The most appropriate outcome for the 
analysis is death rate after five years. Although outcome after five years looks most 
reasonable, we cannot rule out the survival rate of one, two, three and four year 
apart as they may have some information about the state of technology in that year. 
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The next appropriate outcome variable could be the average rate from one to five 
years.  
Table 3.1 (b) shows the summary statistics of other covariates included in the 
analysis. As the table shows, the average pre diagnosis expenditure was $10,039 
which increased to $47,061 in the post diagnosis period. The mean age at diagnosis 
is slightly more than 73 years. We need to remember that it is the mean age of 
diagnosis only among the study populations who are 65 years or older.  
Table 3.1 (b): Summary Statistics of some key variables 
N=120816 
  Summary Statistics 
Variables Statistic Std. Dev. 
Mean pre Expenditure  $10,039 26476 
Mean Post Expenditure  $47,061 47844 
Mean of difference between pre and post expenditure  $37,021 50999 
Mean age in years  73.27 5.58 
Mean of Charlson Comorbidity score  2.25 2.02 
Race: White 83% 0.37* 
Race: African American 10% 0.30* 
Race: Other 7% 0.25* 
Metastatic 4% 0.19* 
Unstaged 7% 0.26* 
Residence in metropolitan areas 59% 0.49* 
Therapy Started 81% 0.39* 
Mean of college education or higher by zip code  28% 17.03 
Mean income by zip code $50,654 21340 
Notes: * Standard deviations are calculated in terms of proportions, not in 
percentage  
 
Charlson‟s comorbidity score shows the comorbid conditions that provide 
information about the distributions of pre-existing conditions among patients 
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affecting total health care expenditure for them. The distribution of race is a little 
different from what the overall US population looks like.  The percentage of white 
population is slightly larger compared to the overall population distribution14. 
However, even though the incidence is higher in the Black population15, the data 
show a smaller representation of Blacks compared to their overall population share 
(12.3%). A substantial population lives in big cities given by metro locations (59%). 
Table 3.1 (c) Mean expenditure by year of diagnosis 
 
Year 
 
N Obs. (%) 
Total N = 
120,816 
Pre Expenditure Post Expenditure Differenced Exp. 
Mean 
$ 
Std 
Dev 
Mean 
$ 
Std 
Dev 
Mean 
$ 
Std Dev 
1991 3,279 (2.71) 10582 30604 42340 40575 31757 47346 
1992 12,299 (10.18) 9056 22216 40069 37959 31012 41339 
1993 10,594 (8.77) 8567 21050 38797 39768 30230 41809 
1994 8,875 (7.35) 8322 20754 38735 41654 30413 44221 
1995 8,020 (6.64) 8231 19737 37788 43362 29557 45418 
1996 7,449 (6.17) 8700 22188 39322 36534 30622 39707 
1997 7,689 (6.36) 8629 24610 41004 37446 32375 41878 
1998 7,233 (5.99) 9513 27503 45347 42184 35834 45435 
1999 7,872 (6.52) 9431 22761 46119 40715 36688 42980 
2000 15,317 (12.68) 11016 28452 51088 46968 40072 51225 
2001 15,845 (13.11) 11478 29503 57071 58012 45593 61184 
2002 16344 (13.53) 12939 34584 61810 62391 48871 66978 
 
                                               
14
 According to the US Census Bureau, Whites, Blacks and Hispanic and Asian population were 75.1%, 12.3%, 12.5% 
and 3.5% respectively as of year 2000. (Source: http://factfinder.census.gov/servlet/SAFFFacts).  
15
 Source Central for Disease Control (CDC) website (http://www.cdc.gov/cancer/prostate/statistics/race.htm).  
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The table also provides information about the stage of cancer at diagnosis. 
Only the malignant and unknown stages are included in the analysis as they are 
assumed to have a significant impact on the spending. Among all diagnosed with 
cancer, 81% of them start therapy within one year of diagnosis.    
SEER does not provide individual level information on income and education. 
These information are available only through external sources such as census 
tracts. The database has zip code level information on income and education. The 
mean of zip code level mean income was $50,654 and mean of percentage of 
individuals with college or higher degree in zip code level was 28% in the sample.  
Table 3.1 (c) shows mean expenditures by year of diagnosis. Both pre and post 
diagnosis expenditure show similar trend—the post expenditure fall until 1995 and 
then start rising again. The pre-expenditures fall further until 1996 before they 
start rising. The differenced expenditures have the same trend as post expenditure. 
The total growth of pre expenditure was 22 percent over the entire period 1991- 
2002. However, the post expenditure grew by 46 percent during the same period. 
The differenced expenditure grew by the largest percentage, i.e. 54 percent during 
that period. 
It is assumed that the differenced expenditure is the expenditure attributable 
to the diagnosis of cancer. The growth rate of 54 percent, which is net of regular 
growth in spending, is supposedly caused by advances in the care of prostate cancer.  
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Table 3.1 (d) Distribution of sample and expenditures by SEER registry locations 
SEER Registry 
Locations 
N Obs 
(%) Variables Mean $ Std Dev 
02=Connecticut 11769 
(9.7) 
Pre Expenditure 
Post Expenditure 
Diff Expenditure 
8594 
43230 
34636 
24013 
37679 
42836 
20 = Detroit 19116 
(15.8) 
Pre Expenditure 
Post Expenditure 
Diff Expenditure 
10579 
53918 
43339 
21534 
43577 
46217 
21 = Hawaii 2503 
(2.1) 
Pre Expenditure 
Post Expenditure 
Diff Expenditure 
7210 
43945 
36736 
18092 
36798 
39528 
22 = Iowa 12645 
(10.5) 
Pre Expenditure 
Post Expenditure 
Diff Expenditure 
6328 
29643 
23315 
15745 
28203 
30645 
23 = New Mexico 4698 
(3.9) 
Pre Expenditure 
Post Expenditure 
Diff Expenditure 
6931 
35118 
28187 
18546 
37201 
39657 
25 = Seattle 9791 
(8.1) 
Pre Expenditure 
Post Expenditure 
Diff Expenditure 
6095 
32671 
26575 
14167 
27602 
29779 
26 = Utah 5886 
(4.9) 
Pre Expenditure 
Post Expenditure 
Diff Expenditure 
6331 
28288 
21957 
15289 
26602 
29771 
27 = Atlanta 
metropolitan 
5600 
(4.6) 
Pre Expenditure 
Post Expenditure 
Diff Expenditure 
8045 
43314 
35269 
17303 
32095 
34446 
37 = Rural Georgia 404 (0.3) Pre Expenditure 
Post Expenditure 
Diff Expenditure 
8206 
39754 
31547 
16302 
33596 
36189 
42 = Kentucky 3848 
(3.2) 
Pre Expenditure 
Post Expenditure 
Diff Expenditure 
9193 
44353 
35160 
19210 
35033 
38288 
43 = Louisiana 3492 
(2.9) 
Pre Expenditure 
Post Expenditure 
Diff Expenditure 
13079 
49291 
36213 
27632 
45177 
49106 
44 = New Jersey 8863 
(7.3) 
Pre Expenditure 
Post Expenditure 
Diff Expenditure 
14136 
69351 
55215 
37202 
69696 
73836 
88 = California 32201 
(26.6) 
Pre Expenditure 
Post Expenditure 
Diff Expenditure 
13271 
55713 
42442 
35664 
59554 
64820 
 
 
74 
 
 
 
 
Figure 3.1 Trends of PCa caused death rate and one year health expenditure 
from 1991 to 2002 
Finally, Table 3.1 (d) shows mean expenditure and frequency distribution by 
SEER locations. Note that in regression equations, a full set of SEER location 
dummies are used.  
Figure 3.1 shows the visual picture of the expenditures and outcome 
variables over the study period. Only three outcome variables and one expenditure 
variable are used in the figure for comparison. In order to make comparison easier, 
the latest value of each outcome variable was fixed at 50 and all previous years‟ 
values were adjusted accordingly.  
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The current death rate is stable to begin with and starts falling from year 
1994. The death rate after five years is falling throughout. The average death rate 
is somewhere in between the two other. The health outcome is continuously 
improving over time. However, the expenditure trend is somewhat different. It is 
stable or slightly falling until 1995 after which is shows a rising trend. The trend of 
expenditure is sharp particularly after 1999.  
 
3.5 Results 
The results from single equation estimation and simultaneous equation 
estimation are obtained. Table 3.2 shows the results from single equation model 
using the non-linear technique. The results for each variable are obtained from 
separate equation, so the table shows results from six estimating equations. The left 
hand side variable is the differenced expenditure and the variable of interest on the 
right hand side is death rate. Each equation included a set of control variables that 
included patients‟ age, race, comorbidity, treatment status, stage of cancer, dummy 
for metro residence, and full set of dummy variables for geographic locations defined 
by SEER registries. Full equation estimates are shown in Appendix B.  
 All coefficients of interest are highly significant. The first year outcome has 
the highest association with expenditure and fourth year outcome has the lowest. It 
shows that increasing the gap between diagnosis year and outcome year 
continuously lowers the magnitude of impact until year four. The fifth year 
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outcome, however, has a larger impact even that of third year. Predictably, the 
average of outcomes from year one to year five has a moderate impact on spending.  
  
Table 3.2: Results from single equation model 
Dependent variable: One year expenditure following diagnosis 
Variables of interest Coefficient Standard 
Error 
z-
statistic 
P > 
|z| 
Implied 
marginal 
effect (in $) 
First year -0.0059 0.000155 -38.20 0.00 -201 
Second year -0.0053 0.000142 -37.46 0.00 -181 
Third year -0.0050 0.000138 -36.99 0.00 -173 
Fourth year -0.0051 0.000141 -36.48 0.00 -174 
Fifth year -0.0053 0.000144 -36.54 0.00 -179 
Average (first-fifth year) -0.0054 0.000144 -37.25 0.00 -183 
 
Since the coefficients of estimation are from a non-linear model with log 
transformation, a proper interpretation of those results needs to transform them in 
dollar term. The implied marginal impacts are also calculated in the dollar term 
and put in the last column. The marginal effects in dollar terms show that a unit 
reduction in the current year death rate causes the average one year post diagnosis 
expenditure to go up by $201. The result for 5 year after diagnosis is $179 and 
average for year 1 through year 5 is $183.   
Table 3.3 shows the results from simultaneous equation model. The variables 
of interest are the same as in the single equation model. The control variables are 
the same with the modifications explained in the issue of identification above. To 
keep the table simple, the estimates for control variables are not reported in the 
table (full equation estimates are shown in Appendix B).  
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Table 3.3: Results from simultaneous equation model 
 Variables of interest Coefficient Standard 
Error 
z-
statistic 
P>z 
 
First year -206 5.37 -38.35 
 
0.00 
Second year -186 4.95 -37.58 0.00 
Third year -179 4.83 -37.10 0.00 
Fourth year -180 4.93 -36.42 0.00 
Fifth year -185 5.07 -36.50 0.00 
Average (first-fifth year) -188 5.04 -37.31 0.00 
 
All coefficients are statistically and economically significant. The current 
year outcome has the highest impact on spending while the outcomes resulting in 
four years have the lowest impact. In dollar terms they are -206 and -180 dollars 
respectively. Note that the estimated coefficients are in dollar terms now and there 
is no need of conversion as in the single equation model. The coefficient on fifth year 
outcome (-$185) is slightly larger than that of the third year outcome (-$179). The 
coefficient on five year moving average is -$188.  
 We need to carefully interpret the results from single equation and 
simultaneous equation models in order to get meaningful economic implications. 
The main explanatory variable of interest was the index of technology proxied by an 
outcome that closely indicates advances in cancer care. The death rate associated 
with prostate cancer has been consistently decreasing. Table 3.1 (a) above shows the 
annual death statistics. The death rate resulting from PCa for 65+ age group 
78 
 
 
decreased by 103 points from 277 in 1991 to 174 in 2002 in every 100,000 male 
population. If we take a moderate estimate of $185 as marginal spending, the total 
spending per patient would be $19,055 for this whole achievement. It means that to 
bring down the death rate from 277 to 174, per patient first year spending increased 
by $19,055 in average16 (assuming linearity).   
More interest lies in the cost of one PCa death avoided. During that period, 
the cancer incidence rate was about 1,000 in seniors aged 65 or above in the same 
100,000 population (NCI, 2010). The estimated moderate cost of reducing the death 
by one point is $185 spent per patient in the first year. There are 1000 new patients 
in the population pool. It means if $185 more is spent on each incident case in the 
first year, one less person will die of cancer. So one PCa death avoided is calculated 
as 1000 times 185, which is $185,000. Using the same $185 rate, the total cost of 
avoiding one death due to prostate cancer is $185,000 in the 65 and plus population. 
This is however, only the first year incremental spending not the total cost of 
avoiding one PCa death. Because most PCa patients get most intensive treatment 
within a year of diagnosis, $185,000 is the very large chunk of lifetime total 
spending.    
3.6 Discussion and conclusion 
The health care expenditure of prostate cancer patients has increased by 54 
percent from 1991 to 2002. The average annual growth rate17 during that time is 
                                               
16 This is simply calculated by multiplying the marginal cost of per unit reduction ($185) with total 
reduction (103).  
17 It is also known as exponential growth rate.  
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about 3.9%.  The causes underlying this growth can be many. However the role of 
technological change has a significant impact in this long run growth of spending.  
 How much of this change is attributable to overall technological change is the 
main research question for this chapter. Finding the answer to this question is 
possible if we can measure the technology. An objective measure of technology in 
health care is not available, and no such attempt has been made in health 
economics literature. It is also beyond the scope of present research.  
 I have proposed and used a proxy measure of technology given by health care 
outcomes. These proxy measures are based on the assumption that any long term 
improvement in health care outcome results only when we have a better knowledge 
of medicine. This is also known as technological improvement. So, technological 
change is defined as any change in the practice of medicine that brings improved 
outcomes for the patients.  
 We also need to remember that all changes that become the part of 
technological changes are not equally important. Some are more important than 
others. Using the outcome as a measure of technological change duly weights all the 
changes in the measure of technology. Changes that are more effective are given 
more weights meaning a faster growth of technology in health care.  
 Two most feasible candidates that provide suitable measure of technological 
change in health in prostate cancer care include post diagnosis survival rate and the 
rate of prostate cancer related deaths. Both measures have their own strengths and 
weaknesses. However, I found that death rates related to prostate cancer comprised 
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a simpler and more easily available measure of technological progress in prostate 
cancer care.  
 Using the health outcome as a measure of technological change invites 
questions from the standpoint of estimation. Two important assumptions are made 
in order to provide the basis of analytical design for this chapter. The first 
assumption is no reverse causality from expenditure to outcome. It means that 
expenditure cannot affect potential outcome. The second assumption allows the 
outcome and expenditure to be simultaneously determined. For the first 
assumption, a single equation non-linear regression model is used in estimation, 
whereas for the second assumption, a two equation simultaneous equation model is 
used for estimation.  
 The results show that outcome alone explains more than $19,000 increase in 
health care spending due to technological change during that period. Using the 
population level statistics, the first year cost of one death avoided due to prostate 
cancer is $185,000 for the study period. These numbers make more sense if we 
know about the average life expectancy of people diagnosed with prostate cancer in 
65 or above age group.  
Additional conclusions can be made about the cost effectiveness of the 
technological change. The average age at diagnosis of PCa was 75 years18 in the 
study period. The average life expectancy of male aged 75 years was 84.39 in 1991 
and 85.7 years in 200219. This implies that avoiding a death from PCa gave about 7 
                                               
18 Calculated from the SEER data.  
19 These data are available from the Actuarial Life Tables by Social Security Administration.  
81 
 
 
additional life years in the period. The first year cost of additional life year from this 
perspective is about $26,000.  
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CHAPTER 4 
MEASURING THE IMPACT OF SELECTED TECHNOLOGIES 
 
4.1 Introduction 
There are two questions in the relationship between new technologies and 
health care expenditure or cost that draw specific interest. First, what is the extent 
to which the increased expenditure is associated with the technological change at 
both aggregate and disaggregate levels? In the aggregate level, the interest lies in 
the impact on expenditure of overall technological change in medicine. In the 
disaggregate level, this question amounts to measuring the incremental cost of a 
specific technology with or without respect to the benefits it generates.  
Second, what are the different ways a new technology enters the cost or 
expenditure function? The second question goes beyond the belief that new 
technologies increase (decrease) health care cost or expenditure because they are 
expensive (cheap). Along with new technologies, other factors may come into play. 
This fact essentially leads to the conclusion that any effort to control cost or 
spending associated with new technologies requires a good understanding of the 
ways a new technology affects cost. This chapter focuses on the second question 
with respect to the recent innovations in external beam radiation therapy to treat 
prostate cancer.  
Usually technological change happens through gradual improvements and 
innovations on existing practices, techniques and treatments. The gradual and 
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subtle nature of technological change poses empirical challenges to define and 
measure accurately the overall technological change and its aggregate effect on cost 
and spending. In contrast, examining the effect of specific innovations is more 
feasible, precise, and therefore more attractive. Also, evidence from these specific 
innovations may be applicable in other comparable situations. In this light, the 
present study examines recent innovations in prostate cancer treatment—three 
dimensional conformal radiation therapy (3D-CRT) and intensity modulated 
radiation therapy (IMRT)—among Medicare patients in the United States. 
This study seeks to answer the question how the health care expenditures 
behave over time after those innovations in external beam radiation therapy come 
into effect. The main goal of this research is to see the dynamics of the effect of the 
new therapy into cost or spending. It is plausible to assume that a new treatment 
may cause a onetime change in cost without affecting the rate of its growth. In other 
words it may only change the level of spending rather than its growth at the patient 
level. The alternative possibility is that new technologies also impact the growth of 
the unit cost of care. In accordance with the specific aim stated in Chapter 1, the 
hypothesis for this chapter is stated as follows. 
Hypothesis: For individuals receiving 3D-CRT and IMRT: 
H0.4.1: The growth of expenditure is not significantly different from the 
expenditure of those receiving standard treatment in the study period.   
H1.4.1: The growth of expenditure is significantly different from the 
expenditure of those receiving standard treatment in the study period.   
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To explore this hypothesis, I estimate the historical trend of the patient level 
incremental cost of new treatments compared to the existing treatment. The long 
term trend of the incremental expenditure resulting from the use of a new 
treatment will help explain the dynamics of the relationship between treatment 
innovations and health care costs.  The reminder of the chapter is organized as 
follows. Section 2 discusses recent literature about technological change in health 
care and its impact on cost and spending. In section 3, I discuss the analytical model 
of measuring the effect of the change in technology on expenditure. Section 4 
includes the data and descriptive statistics. Finally, in sections 5 and 6, empirical 
results and their implications are discussed.     
4.1.1 Innovations in external beam radiation therapy 
Radiation therapy is one of the most common treatment options for various 
conditions including different cancers (NCI, 2009). Surgery and radiation are the 
two most commonly used treatments of prostate cancer. Radiation therapy is 
administered internally and externally. The former is also called Brachytherapy. 
Externally provided radiation is known as external beam radiation therapy (EBRT). 
Among the more recent innovations in radiation therapy, a three dimensional 
conformal radiation therapy (3D-CRT) was developed and used from late 1980s 
(Denmeade and Isaacs, 2002). A more advanced form of radiation treatment called 
intensity modulated radiation therapy (IMRT) came into use from the late 1990s. 
3D-CRT has now become a commonly used practice (Speight and Roach, 2005, Mell 
et al., 2005).  
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3D-CRT involves a complex process of creating a three dimensional images of 
tumors from 3D digital data sets and delivering highly focused radiation to cancer 
cells while sparing normal adjacent tissue. (PAMF, 2009). Using conventional two-
dimensional system, high dose and precise delivery is restricted as there is 
increased risk for acute and late toxicity (Kannan et al., 2005). There is additional 
amount of time and resources used in 3D-CRT over the conventional method 
particularly due to treatment planning. IMRT is an advanced form of 3D-CRT. 
IMRT has favorable outcomes compared to 3D-CRT in terms of rectal and bladder 
toxicity although both high dose treatments improve biochemical outcomes among 
all risk group of patients (Zelefsky et al., 2001).   
Prior to these innovations in EBRT, a two dimensional standard radiation 
therapy (SRT) was used. Both new treatments are more costly than the treatments 
they replaced. In 1995, 3D-CRT needed 12% more technical and 38% more 
professional relative value units (RVUs) (Perez et al., 1997). IMRT requires more 
resources than 3D-CRT or conventional technique in terms of treatment planning 
and delivery time, computer hardware and software upgrades and physics quality 
assurance (Konski, et al., 2006). 
4.2 Theoretical Construct 
4.2.1 The treatment effect 
I first discuss a general model20 to evaluate the impact of a particular 
treatment, and then I discuss the empirical strategies used for this study. Let us 
                                               
20 Here I follow the standard model from the literature. For more see Heckman et al. (2006a, 2006b), Basu et al. (2007) 
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assume a treatment scenario with two alternative treatments, 0 and 1. Let     and 
    be the potential outcomes to individual   from treatment 0 and treatment 1 
respectively. These outcomes are defined as 
               
               
where       and       are the expected values of    and    respectively and    is a 
vector of observed covariates.     and     are unobserved random variables with an 
assumption that         . The effect of choosing treatment 1 versus treatment 0 is 
simply defined as           . In most treatment scenarios, treatment effects     
and     are not observed for the same individual. If     , we observe    and if     
, we observe   . The outcome equation for observed   conditional on treatment 
participation can be written in the form of a switching regression model21 given as 
               
                       
                           
The second and third lines of (3) result from the first line, equation (1) and 
rearrangement of the terms. We can rewrite (2) as a standard regression model as 
           
However, (3) is not a standard regression model that we can estimate using 
the least square regression. There is a strong possibility that there exists a selection 
bias that individuals whose outcomes would have been different without treatment 
                                               
21 Also known as Quandt, Neyman-Fisher-Cox-Rubin-Roy model (Heckman and Vytlacil, 1999, Heckman, Urzua and Vytlacil 
2006a, Basu et al. 2007, Imbens and Angrist, 1994). 
(2) 
(3) 
(1) 
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could be the ones that select into the treatment. Note that I seek to find         
     Equation (2) can be rewritten in the form of average causal effect of selecting a 
treatment known as average treatment effect of the treated (ATET) given by the 
formula (due to Angrist and Krueger, 2000) as 
                                                              
                                                  
where the last is a bias term showing the additional effect on the treatment group 
had they not selected the treatment. Note that the bias term disappears if     is 
randomly assigned.  
4.2.2 Estimation of Average Treatment Effect: Identification and 
Empirical strategy 
I wish to estimate ATET given in equations (2)-(4). Let us define propensity 
score as                  which is the probability of individual   having been 
assigned to treatment 1. The propensity score is our identification tool. The 
identifying assumption in this case is that after conditioning on all of the observed 
characteristics that are known to affect treatment selection given by the propensity 
scores, both treatment and non-treatment groups are comparable, which can be put 
as,  
                                                                                    (5) 
Given this identifying assumption (equation (5)) the ATET is constructed as follows: 
                     E                                          
                                                       E                                          
(4) 
(6) 
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where                               e is a random variable that represents 
the set of differences in mean outcomes by treatment selection corresponding to 
each value taken by      . In order to estimate (6) the method of matching on 
propensity score is used.  
4.2.3 Reducing the bias and further identifying assumptions 
Matching estimation is based on the assumption that selection is on 
observables. Given the estimation model using matching technique, we cannot rule 
out the presence of selection bias due to selection on unobservables. In this scenario, 
the identifying assumption given by (5) above is too strong. Heckman, Ichimura and 
Smith (1997)  and Heckman, Ichimura and Todd (1998) extend the matching 
method to include a semi-parametric conditional difference-in-differences (d-i-d) 
matching estimator with a weaker identifying restriction. A d-i-d matching 
estimator removes the bias associated with fixed factors such as individuals‟ time-
invariant characteristics. From equation (4) the bias is defined 
                                                            
For d-i-d matching, the identifying assumption is:  
                                            
where the subscript    and   denote the pre-treatment and post-treatment outcomes. 
The empirical method to estimate ATET given by equations (4, 6) is the matching 
estimator given as:  
(7) 
(8) 
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Here           is added as a weight that accounts for heteroskedasticity and scale. 
     and      are defined as              and              for treatment and 
comparison groups respectively. Matches for each participant are constructed by 
taking weighted average over comparison group members. Among the various 
weighing schemes, local linear matching is the most suitable for d-i-d estimator 
(Heckman et al. 1997). The local linear weight is given as: 
            
              
 
                                   
                            
                  
 
 
where       
     
   
  is a kernel function and     is a bandwidth parameter. Using 
local linear weight instead of other weights such as kernel weight causes conversion 
faster at boundary points and adapt better to different data densities.  
 
4.3 The empirical work 
4.3.1 Estimation strategy and data  
This study uses the SEER Medicare-linked database which is created linking 
two large population based sources of data. The data from Surveillance, 
Epidemiology and End Results (SEER) program of cancer registries is linked to data 
from Center for Medicare and Medicaid Services (CMS) of persons‟ Medicare claims 
(9) 
(10) 
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for all covered services. The SEER part of data contains demographic, clinical and 
cause of death information for persons with cancer.  
The Medicare part of data contains information associated with all eligible 
claims for corresponding cancer cases from SEER data. The Medicare part also 
contains information on date of service, diagnosis, procedures, provider type, claims 
and payments, and inpatient stays covered under the Part A and B of the Medicare 
program. Within the Medicare data, there are three sources of data—inpatient, 
outpatient and carrier claims. Medicare inpatient claims include all Part A short 
stay, long stay, and skilled nursing facility by calendar year. The outpatient data 
contain all Part B claims from institutional outpatient providers including hospital 
outpatient departments and other clinics and facilities. Carrier claims, also known 
as National Claim History (NCH) records, includes all Part B claims from 
physicians and other non-institutional providers. The SEER database currently 
covers 26 percent of the US population by its 16 registry sites across the United 
States.  
4.3.2 Case selection and sub-samples 
This study uses only prostate cancer cases from the SEER data. The 
population studied includes all Medicare patients in the SEER data who were 
diagnosed with and treated for non-metastatic prostate cancer from 1991 to 2002 
and who received external beam radiation therapy (EBRT) as their definitive 
treatment.  
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Current Procedural Terminology (CPT) codes22 were used to identify patients 
who received conventional standard radiation therapy (SRT), 3D-CRT and IMRT. 
To be eligible for inclusion, the patient is required to receive treatment planning for 
radiation therapy given by CPT codes 77260-77299. Receipt of three dimensional 
treatment planning (CPT code 77295) was used to identify 3D-CRT cases and EBRT 
treatment delivery codes G0174 and 77418 were used to identify IMRT cases. From 
these selected cases, patients who received Brachytherapy only were removed. 
Recipients of SRT were classified as the control group and the recipients of new 
treatments were regarded as the treatment group. The dataset was created by 
combining SRT with 3D-CRT and IMRT with dichotomous variables indicating 
treatment and control groups.   
 
Figure 1: Selection of subsamples 
 
                                               
22 Comprehensive list of codes were obtained from Wong, et al. (2006).  
All prostate cancer patients 
receiving EBRT between 1991 and 
2002 
Control Group 
 All patients receiving SRT 
 
Treatment group: IMRT                           
All patients receiving IMRT  
Treatment Group 1                       
   All patients receiving 3D-CRT 
Treatment Group 2                        
 All patients receiving IMRT  
 
Subsample 1 
 Treatment group: 3D-CRT 
 Control group: SRT 
 
Subsample 2 
 Treatment group: 3D-CRT & IMRT 
 Control group: SRT 
 
Subsample 1-1 
One year expenditure 
N=58,909 
 
Subsample 1-2 
Two year expenditure 
 
Subsample 2-1 
One year expenditure 
N=62,232 
 
Subsample 2-2 
Two year expenditure 
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Only those whose claim records were available for at least one year after and 
six months before the treatment date were included and those who are enrolled in 
HMOs were excluded.  After these inclusion criteria, 64,157 cases were eligible for 
the study. Finally, sub-samples were created combining different treatment groups 
and further classifying subjects into those having one year of claims and those 
having two years of claims. Cases having less than one year (or two year) of claim 
history from the start of the treatment date were removed from one year (or two 
year) subsamples. The subsamples that include two year expenditure have fewer 
observations because not all selected cases had at least two year worth of records 
available.  Figure 1 shows how subsamples were created with number of 
observations.   
4.3.3 Key Variables and descriptive statistics 
Treatment choice: 
  Figure 2 shows the trends for treatment choices for the whole study period 
among patients who received external radiation therapy. All diagnosed patients 
receiving SRT were treated as reference group. For the treatment group, there are 
two other groups: 3D-CRT and IMRT. In the first subsample, SRT cases are 
combined with 3D-CRT cases only. In the second subsample, both 3D-CRT and 
IMRT cases are included as treatment group.   
Expenditure:  
The key variable for this study is the difference between the pre treatment 
and treatment period all-cause health care expenditures for one and two year 
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periods. Expenditure in any period was calculated by aggregating all inpatient, 
outpatient and physician claims for that period. Nursing home, hospice or 
prescription drug claims were not included. The cutoff date for pre treatment and 
treatment period expenditure was the date 90 days before the date treatment 
planning was started. In case date of diagnosis was less than 90 days before 
treatment planning, then  the date of diagnosis was used as the cut off date. One 
year expenditure for the treatment period was calculated for 365 days after the 
cutoff date and two year expenditures were calculated for 730 days after the cutoff 
date. If expenditures were not available for the full treatment periods, mainly due 
to patients‟ deaths, the patients were excluded. Pre treatment expenditures were 
calculated for the same length as treatment period expenditures. If records of claim 
were not available for the full one or two year pre treatment periods, then they were 
imputed for the remaining period using average daily expenditures. However, 
patients having less than 180 days of pre-treatment claims were removed.  
Another adjustment was made in the treatment expenditure of people in the 
last year of their life. If anyone died within one year of treatment period, their 
treatment expenditure is distorted because of increased cost in the end of life care. I 
used the estimates from earlier studies (Lubitz, and Riley, 1993 and Hoover et al. 
2002) to adjust the last year of life expenditures. Finally, the differenced 
expenditures were found by subtracting the pre-treatment expenditure from the 
treatment period expenditure. All expenditures are adjusted for current rate of 
inflation using the consumer price index and are expressed in 2005 dollars.  
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The study uses claims rather than reimbursements as a measure of 
expenditure for a number of reasons. First, it is assumed that the cost of new 
technologies, which essentially enters the cost as an input cost, is more directly 
reflected in the provider claims without any lag. On the other hand, Medicare 
reimbursements rates might be less sensitive to the true cost of new treatment than 
claims. Second, the information about the payment might be incomplete in the 
dataset because payments are made from different sources. Third, the main purpose 
of this study is to see the incremental cost of new treatments using differenced 
rather than absolute expenditure values. So, differencing and using control group 
will take care of much of the bias resulting from the use of claims.  
4.3.4 Summary Statistics 
Table 1 shows the summary statistics of the variables used in the empirical 
estimation for all 4 subsamples by treatment groups. All variables included in the 
table except treatment period expenditure and differenced expenditure are used to 
calculate the propensity score. The continuous age variable rather than categorical 
variables is used in the empirical model. In both samples, notably 3D-CRT group 
have higher pre-treatment expenditure, lower co-morbidity score and lower gap 
from diagnosis to treatment. Also, socio-economic differences also seem to have 
played role in treatment choice.  
Figure 2 shows treatment choice over time for all treatment groups in 
subsample 2-1. Since samples 1-1, 1-2 and 2-2 are only the subset of 2-1, treatment 
choice over time for subsample 2-1 is more realistic. The proportion of people 
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receiving 3D-CRT grows continuously until 2001 after which it starts falling. The 
reason for the fall in 3D-CRT seems to be another new treatment IMRT which came 
into effect right around that time. So, those people who otherwise might get 3D-
CRT may have received IMRT decreasing the proportion of 3D-CRT. The choice of 
IMRT sharply increases in 2001 and 2002. The proportion of patients receiving SRT 
continuously declines from near 100 percent in 1991 to 16 percent in 2002.   
 
 
Figure 4.2: Treatment choice over time 
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Table 4.1: Summary Statistics for all subsamples 
  3D-CRT only 3D-CRT and IMRT 
  One Year Expenditure (1-1) Two Year Expenditure (1-2) One Year Expenditure (2-1) Two Year Expenditure (2-2) 
Variables 
 
 
SRT 
 N= 
35355 
 
3D-
CRT 
N= 
20978 
 
 
Overall 
N= 
56333 
 
 
SRT  
N= 
29503 
 
3D-
CRT 
N= 
19925 
 
 
Overall 
N= 
49428 
 
 
SRT  
N= 
35355 
3DCR
T and 
IMRT  
N= 
23359 
 
 
Overall  
N= 
58714 
 
 
SRT  
N= 
29503 
3D-
CRT 
and 
IMRT 
N= 
22228 
 
 
Overall   
N= 
51731 
Pre treatment 
expenditure ($) 13855 15351 14423 18248 24027 20620 13855 15992 14737 18248 24878 21196 
Treatment period 
expenditure ($) 54181 75730 62359 67738 96945 79725 54181 78729 64310 67738 100253 82195 
Differenced 
expenditure ($) 40788 60571 48296 48855 72602 58601 40787 62932 49925 48855 75046 60500 
Charlson co-
morbidity score 2.28 1.96 2.16 2.37 1.94 2.2 2.28 1.93 2.13 2.38 1.9 2.16 
Mean length from 
diagnosis to 
treatment (days) 
541 404 489 392 360 376 542 443 501 392 393 393 
Married (%) 75 72 74 75 72 74 75 72 73 75 72 74 
Mean age at 
diagnosis (years) 72.43 72.3 72.38 72.4 72.32 72.37 72.43 72.21 72.34 72.4 72.22 72.32 
Age group (%)   
  
  
 
    
 
    
  
Below 65 7.47 7.47 7.47 6.17 6.95 6.79 7.47 8.02 7.7 6.17 7.57 6.79 
65-69 22.26 21.98 22.15 22.41 22.13 22.34 22.26 22.11 22.2 22.41 22.25 22.34 
70-74 34.54 34.73 34.61 36.42 35.16 35.73 34.54 34.48 34.51 36.42 34.88 35.73 
75-79 25.99 27.08 26.41 26.85 27.32 26.9 25.99 26.72 26.29 26.85 26.96 26.9 
80-84 7.78 7.56 7.7 6.86 7.39 7.05 7.78 7.48 7.66 6.86 7.28 7.05 
85+ 1.96 1.18 1.66 1.29 1.04 1.19 1.96 1.18 1.64 1.29 1.06 1.19 
Races ( %)   
  
  
 
    
 
    
  
  White 84 82 83 85 82 84 84 82 83 85 82 84 
  Black 10 11 10 9 11 10 10 11 10 9 11 10 
  Other 6 7 6 7 7 6 6 7 7 6 7 7 
Zip Code level 
variables (mean)     
  
 
    
 
    
  
Income 25542 26187 25787 25704 26270 25936 25543 26620 25986 25704 26740 26163 
Percentage black 11.57 12.29 11.85 11.39 12.19 11.72 11.57 11.97 11.74 11.39 11.85 11.59 
Percentage white 72.85 72.33 72.65 73.4 72.5 73.03 72.85 72.3 72.62 73.4 72.52 73.01 
Percentage 
Hispanic  10.99 11.01 11 10.66 10.96 10.79 10.99 11.36 11.15 10.66 11.29 10.94 
Percentage with 
college degree 28.35 28.35 28.35 28.56 28.45 28.51 28.35 28.94 28.59 28.56 29.08 28.79 
Percentage with 
less than High 
school 
16.95 17.72 17.24 16.71 17.63 17.1 16.95 17.6 17.22 16.71 17.48 17.05 
Percentage of 
households who 
do not speak 
English well 
5.11 5.41 5.22 4.94 5.38 5.12 5.11 5.63 5.32 4.94 5.59 5.23 
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4.3.5 Estimation of Propensity Scores 
Calculating propensity score of treatment selection is the first step in the 
empirical analysis. In the literature23, logit models are used in order to estimate the 
propensity scores      . For the purpose of this study, I have made some additional 
assumptions in order to estimate the propensity scores. The estimation method is 
more suitable to the nature of the data. 
Using simple logit estimation cannot accurately estimate the probability of 
selecting into treatment as the data are divided in clusters and cohorts. To this 
purpose, two unique characteristics of the data are given consideration.  
First, the dataset used in the study is generated in 13 different SEER 
registries at different locations24 of the US. Owing to historical and practice style 
differences the probability of selecting into a treatment may differ by locations. 
Second, the dataset constitutes a series of repeated cross sections as well as 
longitudinal elements. This makes it possible to define cohorts of people based on 
the time or year the treatment or outcome occurs. For the purpose of current 
analysis, it is most useful to define cohorts of people based on the year they started 
treatments. This is intuitive because the probability of selecting into treatment is 
correlated with years treatment started. Since we are considering the use of a new 
technology, it is highly appropriate to allow for the year effect while constructing 
the probability of selecting a treatment.  
                                               
23 Most notable are Dehejia and Wahba (1999 and 2002) 
  
24 There are 18 SEER locations in 2010. As of 2002, there were only 13 SEER locations.  
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In order to take account of the effect of those clusters and cohorts, a 
multilevel mixed model is used to estimate the propensity score. The propensity 
score function can be defined as  
                                                                                                                  (11) 
where    includes all the factors affecting treatment choice. In estimating this 
equation using a standard model such as generalized linear model it is assumed 
that responses are independent given the covariates X. However, due to the 
existence of multiple cohorts and clusters in the data, there will often be unobserved 
heterogeneity at the cluster level caused by confounders that are either unobserved 
or unknown. For example the adoption of a new technology may be faster in some 
areas which makes some people more likely to chose a new treatment than others. 
So there is dependence among the units due to unobserved heterogeneity at the 
cluster level even for controlling observed heterogeneity.  
In addition, the clusters are crossed with occasions, such as the use of a new 
treatment is crossed with the times when those treatments become available or 
when they become more widespread. We can model this dependence and the cross 
effects by splitting the error term into components for each level (Skrondal and 
Rabe-Hesketh, 2008) and we can rewrite our model (11) as: 
                                              (12) 
where                  and             The error term is now broken into three 
parts where     and     are random intercepts for clusters and years respectively 
and      is residual error term assuming:  
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This is known as two-way error-component model or crossed random effect 
model. To estimate (12) using crossed-random effects model, clusters are treated as 
level-2 units with random intercepts specified for them and years are treated as 
level-3 random intercepts. For level 3 dummy variables for years are constructed 
and the coefficient on dummy variables will be the random intercept imposing 
assumptions of (12). Then the estimating equation of (12) is written as                                                       
                                         
   
     
   
                                                    (13)               
Equation (13) is estimated using maximum likelihood method.  
 
Propensity Scores:  
The propensity scores were calculated using the model specified above. The 
distribution of propensity score is shown by kernel density plots in Figure 3 for two 
subsamples. Figure 3a shows the distribution of propensity scores for subsample 1-1 
and 3b shows that for subsample 2-125. The graph also shows the overlap of the 
support where we can identify the treatment effect. Although there is a good deal of 
overlapping, we cannot identify the treatment effect over the entire (0, 1) support26.  
 
 
                                               
25 The distribution of propensity scores for samples 1-2 and 2-2 are not shown but very similar to 
those that are shown.  
26 Identification of treatment effect by propensity score matching requires that there are matching 
scores of treatment and control group. The distribution of propensity scores show that it is not evenly 
distributed in (0, 1) support. Propensity score for either group is not available towards the higher 
end of the support.  
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4.3.6 The issue of identification 
The identifying assumption in propensity score model is that conditional on 
propensity score, the choice of treatment and outcome are independent. Once we 
control for all pre-treatment information, any change in post-treatment expenditure 
is purely random—patients incur expenditure increases due to other changes (such 
as new illnesses) irrespective of treatment status. However, the treatment 
assignment is not randomized and it is also possible that there are unobserved 
factors that affect the choice of treatment and spending. The major identification 
issue is how to minimize the potential bias arising from the possible endogeneity of 
treatment selection. In our model, endogeneity will be present if a particular group 
of patients who select into a particular treatment also have higher or lower 
expenditures than others. For example, if sicker or higher cost patients select more 
advanced technology then the effect of treatment cannot be identified or it will be 
overestimated. Similarly, same thing will happen if high cost providers are more 
likely to offer more advanced treatments.  
There are some arguments to rule out the existence of endogeneity or rule out 
its significant impact if there is any. The first argument is that there is some sort of 
randomization in treatment assignment because people select a particular 
treatment versus another based on time, location and provider. This denies a 
possibility that sicker or high cost patients are systematically subjected to a specific 
treatment. The effect of year or location in treatment selection is observed and 
included in the propensity score model including many other pre-treatment 
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variables that might affect the treatment selection. The second and stronger 
argument is based on the use of pre treatment expenditure—the critical identifying 
technique used in this study. The use of pre-treatment expenditure will eliminate or 
minimize any patient or provider level fixed factor that subjects patients to 
treatment or no treatment based potential treatment expenditures.  
  
  (a) Distribution of propensity score for 
sub-sample 1-1                         
(b) Distribution of propensity score for 
sub-sample 2-1                         
 
Figure 4.3: Kernel density plots of propensity score distribution for two subsamples 
 
4.4 The Results 
Empirical estimation uses the strategy and identification technique 
explained above. In addition to the estimates made for the full sample, further 
estimates are made for all treatment cohorts created based on the year they started 
treatment. So estimates are made for each year for the study period 1991-2002. This 
allows us to see how spending changed over time after the adoption of a new 
technology.  
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4.4.1 The effect of 3D-CRT only 
In order to see how the effect of a particular innovation on spending behaves 
in the long run, I first estimate the incremental effect of 3D-CRT excluding all 
IMRT cases. The estimated results using propensity score local linear matching 
using d-i-d extension are presented in Table 2. Overall, 3D-CRT has a highly 
significant effect on both one and two year spending. The differential spending for 
one and two year periods are $8,627 and $12,242 respectively. The cohort estimates 
show that the incremental effects are not statistically significant for the first 3 
years of treatment 1991-1993. The treatment effects are both statistically and 
economically significant for the rest of the years. 
Table 4.2. Summary of the results from empirical estimation for all subsamples and cohorts 
 
  3D-CRT only 3D-CRT and IMRT combined 
  One Year 
spending 
Two Year 
spending 
One Year 
spending 
Two Year 
spending 
 
Sub-
samples/ 
Cohorts 
 
Difference 
($) 
 
T-
stat 
 
Difference 
($) 
 
T-
stat Difference 
($) 
T-
stat Difference 
($) 
T-
stat 
1991 $479 0.07 -$4,562 -0.59 $430 0.06 -$5,066 -0.68 
1992 $1,761 0.34 -$310 -0.04 -$1,261 -0.19 -$608 -0.08 
1993 $914 0.35 -$1,026 -0.23 $1,999 0.78 -$1,606 -0.37 
1994 $5,440 2.13 $13,600 3.18 $5,983 2.37 $12,379 2.96 
1995 $11,376 5.67 $13,147 4.45 $11,185 5.59 $13,475 4.61 
1996 $16,074 7.84 $14,422 5.06 $14,984 7.15 $14,298 5.04 
1997 $13,336 8.44 $12,356 5.37 $12,512 7.97 $12,927 5.71 
1998 $13,977 9.30 $14,993 6.50 $14,086 9.27 $14,974 6.51 
1999 $10,195 6.68 $16,612 6.47 $10,829 7.02 $16,905 6.59 
2000 $9,839 7.08 $14,760 5.86 $11,477 8.10 $15,507 6.20 
2001 $8,316 4.34 $11,297 3.85 $11,636 5.82 $14,051 4.71 
2002 $6,319 2.40 $12,641 3.99 $14,136 5.09 $18,003 5.73 
Overall $8,627 12.61 $12,242 12.06 $11,836 16.42 $14,724 14.14 
Notes: Spending is reported in 2005 constant dollar terms. S.E. are not reported to save space. 
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The trends of differential spending are also presented using the Lowess plots 
in order to smooth out the trends. Figure 4(a) shows the trends for 3D-CRT 
spending for one and two year treatment periods. The long run behavior of 
incremental spending is inverted U-shaped. The incremental spending of treatment 
starts out as low and insignificant for both treatment periods. After a few years, the 
differential spending of 3D-CRT over standard therapy starts increasing and 
becomes substantially higher. Both one and two year differential spending grow 
similarly except that two year spending remains higher for longer time. Towards 
the end of the study period, the differential spending shows a decreasing tendency 
for both subsamples. The initial growth in spending eventually takes a reverse 
trend.  
4.4.2 Adding IMRT 
In order to see how the behavior of spending changes when there is another 
innovation, I added IMRT cases in the treatment group and did a parallel 
estimation as 3D-CRT. In this strategy, the treatment group includes 3D-CRT and 
IMRT cases and control group includes SRT cases. On the one hand, the rationale of 
adding IMRT cases is that like 3D-CRT, IMRT is a new innovation and more 
advanced treatment in radiation therapy and it substitutes 3D-CRT. Patients are 
given either one of the technologically advanced new treatments or conventional 
therapy. On the other hand, trend analysis of IMRT alone like 3D-CRT is not 
feasible because of the short span of time that IMRT had been used in the dataset. 
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Although small numbers of cases are available for earlier years, a substantial 
number of cases are available only from the year 2000.  
 
             (a) 3D-CRT only                                        (b) 3D-CRT and IMRT 
Figure 4.4. Lowess plots for the trends of estimated incremental expenditure of the 
treatment selection for the study period. 
 
Estimates are made using the same technique as for 3D-CRT and estimated 
results are presented in Table 2. For the whole sample, new therapies account for 
$11,836 and $14,424 spending for one and two years respectively. As in 3D-CRT, 
cohort estimates show that the incremental effects were not statistically significant 
for the first 3 years of treatment 1991-1993 and both statistically and economically 
significant thereafter. The trends of spending are markedly different towards the 
end of the study period, however. The trends are also shown using the Lowess plots 
in Figure 4 (b). With IMRT added, the trends of differential spending for both one 
and two year look very similar with those of 3D-CRT during the first half of the 
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spending become completely different—they mimic the behavior of IMRT as a 
treatment choice (Figure 2). After the introduction of IMRT, the incremental 
spending for new treatments start rising once again.  
4.5 Sensitivity Analysis and Robustness Checks 
The key assumption for identifying the treatment effect is that the choice of 
treatment is independent of any observed factors that also affect the expenditure. 
This study uses the richness of the data and suitable techniques to make sure there 
is no bias associated with unobserved patient characteristics. In order to see how 
robust these estimates are against any misspecification, I do a sensitivity analysis 
and robustness checks in this section.  
The basic identification assumption in the propensity score matching 
analysis is that the factors affecting the choice of treatment are observable and 
there is no confounding between the choice of treatment and outcome. The 
estimation of treatment effect will be biased if there is a confounding between the 
choice of treatment and the outcomes. In the context of present study, the treatment 
effect will be overestimated if the patients who choose more advanced forms of 
treatment are those who tend to consume more or better health care and thereby 
have higher health care spending. Although there is no direct method of measuring 
confounding effects, we can still employ some of the measures to check the 
robustness and sensitivity against specification errors.  
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4.5.1 Sensitivity analysis 
I use the bounding approach (Rosenbaum, 2002; Becker and Caliendo, 2007) 
proposed by Rosenbaum (2002) in order to check the sensitivity of estimated 
treatment effects to any hidden bias. This analysis checks the robustness of 
estimated treatment effects with respect to assumptions about an unobserved 
covariate that is associated with both treatment and response. Although, bounding 
approach is not the test for the existence of the confounding effects, it provides the 
way to determine how strongly an unmeasured variable must influence the 
selection process to undermine the matching estimates. Let         be such a 
confounder and   be the outcome variable which is a continuous variable in our 
case. In a situation when two individuals with similar observed characteristics may 
have different chances of receiving a treatment and bounds on the odds ratio that 
either of the individual will receive treatment is constructed as: 
 
 
 
        
        
   
where       are the probabilities of receiving treatment by individuals   and      . 
The statistic   is defined such that     if both individuals have the same 
probability of receiving the treatment. For    , meaning that there are different 
odds of receiving treatment due to unobserved covariates, the distribution of 
treatment assignments is unknown but bounded with a range of significance levels. 
In order to construct such bounds Mantel and Haenszel (MH) test statistic for 
observed outcome is used. The lower bound suggests the case when treatment effect 
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is underestimated while upper bound is in the case when treatment effect is 
overestimated.   
The bounding approach is applicable when the outcome is binary. Since the 
outcome variable in this analysis is expenditure, which is continuous, a binary 
outcome variable is created for this purpose. The most likely source of confounding 
was the unobserved patient or provider characteristics that may lead high cost 
patient select into advanced treatments overestimating the treatment effect. Mean 
value of the differenced expenditure was chosen to dichotomize the outcomes into 
high and low expenditures. The odds of selecting into treatment are defined as: 
                     
      ,                        
which is the probability that     in each of the four groups defined by observed 
covariates   and the binary transformation of outcomes.  
Table 3 shows the results of the sensitivity analysis. For each sample, overall 
samples and treatment cohorts, I calculated the upper bounds for which the MH 
test statistic is still significant at 1% significance level. This test did not apply to 
cohorts for whom treatment effects were not significant. In the first column, for 
example, the Rosenbaum bound for the overestimation of treatment effect     is 1.4. 
This means that the calculated treatment effect is sensitive to bias that would 
increase the odds of receiving treatment beyond 1.4. However, it will remain 
insensitive if odds are up to 1.4. The highest upper bounds for insensitive regions 
for various samples and cohorts range from 1.2 to 3. The upper bounds for 
estimated treatment effects are smaller for treatment cohorts than for overall 
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samples indicating the smaller probability of selection bias. Further, the bounds get 
larger until the middle of the study period and then they continuously decline for 
the remaining years. Note that having an upper bound greater than 1 does not 
necessarily mean that there is a positive selection bias. The lower bounds for bias 
for estimated treatment effects is not interesting given the assumption of 
overestimation of treatment effect.  
Table 4.3: Estimation of Rosenbaum bounds to check the sensitivity of results 
Cohorts/ Sub-samples 
3D-CRT 
One Year 
3D-CRT 
Two Year 
3D-CRT and IMRT 
One Year 
3D-CRT and IMRT 
Two Year 
            
1991 ‡ ‡ ‡ ‡ 
1992 ‡ ‡ ‡ ‡ 
1993 ‡ ‡ ‡ ‡ 
1994 1.4 1.4 1.2 1.2 
1995 2 1.8 1.8 1.8 
1996 2.8 2 2.8 2 
1997 2.6 1.8 2.6 1.8 
1998 2.4 2 2.4 2.2 
1999 1.8 1.6 1.8 1.8 
2000 1.6 1.4 1.6 1.4 
2001 1.4 1.2 1.4 1.4 
2002 1.2 1.2 1.6 1.4 
Notes:  
   is the upper bound of the odds of receiving the treatment 
‡ denotes results are irrelevant due to the insignificance of the estimates 
 
4.5.2 Robustness Checks 
I also use a parametric approach to estimate the treatment effect using a 
multivariate regression model. In order to control potential bias associated with 
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treatment selection differenced expenditure rather than absolute expenditure was 
used as the dependent variable. Again, differencing was our main strategy to reduce 
the bias associated with patient level fixed effect. Further, I created an indicator 
variable of treatment for each cohort that will capture the treatment effect for that 
cohort. Other independent variables included a host of control variables including a 
full set of year dummies. Generalized Linear Model (GLM) with Log link and 
Gamma distribution was used to estimate the regression model27.  
Estimates from the regression model are presented in Table 4. The estimates 
from parametric and non parametric methods broadly agree although there are 
differences in magnitudes and fluctuations. Note that these two methods are not 
meant to be equivalent in terms of specifications. One year spending for 3D-CRT is 
very close in terms of both magnitude and trend in both methods. The differences in 
two year spending for 3D-CRT are, however, more pronounced at times. For both 
3D-CRT and IMRT combined, the estimates from parametric methods show a 
sudden upward jump and stay or slightly fall before they start rising again unlike 
non parametric estimates when they rise more gradually, remain relatively flat for 
sometimes and tend to rise again.     
4.6 Discussion and conclusion 
This study aimed at analyzing the behavior of health care spending related to 
innovations in radiation therapy over a long period of time. Two innovations in 
radiation therapy were selected for study—3D-CRT and IMRT. Evidence from 3D-
                                               
27 Among various parametric models, GLM model with log link is more suitable for this type of data. See Manning, Basu and Mullahy (2005) for complete 
treatment to the approach.  
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CRT suggests that incremental spending tends to rise after a few years of adoption. 
During the early stage of adoption, the incremental effects were not substantial. 
Spending owing to new treatment not only increased later on, it grew fairly 
consistently for a certain period of time before it started subsiding towards the end 
of 12 year study period 1991-2002. It is interesting and particularly important to 
note that although it is a cost increasing technology (Perez et al., 1995), the cost 
does not seem to be different or to increase all of the time.  
Table 4.4: Parametric estimation of the treatment effects for subsamples and 
treatment cohorts 
Cohorts/ 
Sub-
samples 
3D-CRT 
One Year 
($) 
3D-CRT 
Two Year 
($) 
3D-CRT and 
IMRT 
One Year 
($) 
3D-CRT and 
IMRT 
Two Year 
($) 
1991 -2,738† -3,794† -10,556† -12,029† 
1992 -1,830† -2,015† 2,718† 1,235† 
1993 2,520† 1,824† -2,066† -3,328† 
1994 7,105‡ 6,890* 15,096‡ 15,299* 
1995 11,910* 11,819* 12,669* 12,511* 
1996 15,418* 15,160* 11,829* 12,025* 
1997 12,512* 12,919* 12,337* 12,807* 
1998 12,491* 12,586* 10,259* 10,374* 
1999 7,917* 8,048* 9,656* 9,786* 
2000 8,970* 9,472* 10,560* 11,120* 
2001 6,143* 7,744* 5,568* 7,187* 
2002 5,467* 8,631* 8,264* 12,048* 
Overall 8,341* 10,099* 9, 052* 10,849* 
†  Not significant at 5% level ‡ Significant at 5% level * Significant at 1% level 
 
Another innovation was introduced in radiation therapy towards the end of 
study period. Estimates that include both 3D-CRT and IMRT as new treatment 
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versus the conventional treatment show that incremental spending does not subside 
but keeps increasing after IMRT was introduced. However, it is also noted that 
there was a brief slowdown of the spending growth during the very early stage of 
IMRT adoption. Towards the end of the study period, both one and two year 
incremental spending trends go upwards. The spending growth resulting from 3D-
CRT was maintained from the introduction of IMRT.  
The behavior of spending over time supports different hypotheses about how 
new technologies enter the health care cost and expenditure functions. During the 
initial adoption period, cost of 3D-CRT is not substantially different from the cost of 
conventional therapy. This suggests that cost plays an important role on 
acceptability of a new technology that may not substantially improve outcomes. 
This is also supported by studies (such as Perez et al., 1997) during the early stage 
of adoption that the overall cost of CRT was not different from that of SRT.  
But as acceptance rate grows later in the period, the incremental spending grows as 
well. Perhaps it is the market power of care providers, rather than the actual cost of 
production, that caused the cost of treatment to go up as acceptability increased. 
This further implies, as suggested by previous studies (Keeler et al., 1999), that 
hospitals that adopt new technology before most others may be able to charge more 
due to their competitive edge in the market causing the average expenditure to go 
up.    
The eventual decrease in the incremental cost may come from two reasons, 
installation cost and competition. Health care providers who install new technology 
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based treatment facility may charge more than the normal amount in order to 
recover their installation cost during the initial period (Lotan et al., 2005). This may 
eventually come down after a reasonable period of time. On the other hand, 
competition among providers may also lead to reduced incremental spending as 
almost all service providers adopt the technology, no providers can charge the early 
adoption premiums for the new technology.  
The rising and falling expenditure trend can result from the possibility that 
high cost providers are among the early adopters of new technology. As new 
technology becomes available only few hospitals are very likely to adopt them first 
driving the average expenditures upwards compared to the standard treatment. 
When almost all providers, including low cost providers adopt the technology, the 
average expenditure is very likely to go down.  
The increasing trend of expenditure is reinforced with the introduction of 
IMRT—it seems to repeat the trend of 3D-CRT. This suggests that the adoption of 
new technology by hospitals is motivated by their goal of becoming the leader in 
providing the quality care (Teplensky et al., 1997) while maintaining or increasing 
the flow of revenues and/or profits. The conclusion is that the costs associated with 
innovations in health care do not only change the intercept, they also change the 
slope of the expenditure growth in the long run. This study finds that the nature of 
the growth of spending associated with a single innovation rises first before it starts 
declining. If there are a series of innovations, the upward trend of spending is likely 
to continue as we see the effect of IMRT on the behavior of spending. For additional 
113 
 
 
research, the findings of this study suggest that the role of new technologies to drive 
up cost and spending at least partly depends on the technology adoption behavior of 
the health care providers, such as who adopts the new technology first. The way 
health care market is organized and the speed by which a new treatment is 
expanded are essentially linked with that.   
The scope of the analysis is limited to the behavior of cost of a treatment over 
time without accounting for its effectiveness. Further studies may focus cost-
effectiveness analysis using these findings to draw policy relevant conclusions.  
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CHAPTER 5 
SUMMARY OF STUDY, FINDINGS AND CONCLUSION 
 
For the last couple of decades the US health care spending has been growing 
very rapidly, which is a major source of concern and policy debate at the national 
level. From early 1990‟s the health care spending increased by an average of 
approximately 7 percent (Schoen et al., 2009; Zuckerman and McFeeters, 2006) per 
year. This means that total health care spending is doubling every decade unlike 
the GDP which is growing at a much slower rate. The consequences of rising health 
care cost and spending are many and significant. One of them is the price rationing 
of health care. An increasing segment of US population is without health care 
coverage because it is unaffordable to them.  
Health care reform has received the top priority in national policy reform. 
The goal of such reform is to provide affordable but high quality care to all 
individuals. This implies that controlling the growth of health care cost is one key 
objective of such policy.  
It is widely agreed that technological change in health care is the major 
driver of health care cost and spending. However, there is no agreement in what 
share of contribution is made by technological change. The main purpose of this 
study is to understand the extent of the impact of technological change in health 
care.  
There are two aspects of technological change that are important to know in 
order to understand the role of technological change. The first is what is the extent 
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to which innovations in medicine drive up health care cost and spending? The 
second aspect of technological advancement is the way it affects spending. The 
relationship between new technologies and their associated costs could be 
influenced by several factors in a complicated fashion. How these new technologies 
are produced, financed and marketed may determine the exact impact of their cost. 
Understanding the extent and mechanism by which a new technology actually 
translates into higher cost are main objectives of this study.  
 
5.1 Study design and organization of the report 
This study uses a retrospective research design with observational historical 
data. In order to ensure precision, this study uses only specific group of patients 
with a specific condition. The subjects are Medicare enrolled individuals aged 65 or 
above who were diagnosed with prostate cancer from 1991 to 2002. Specifically, this 
study seeks to measure the association between technological changes and health 
care spending attributable to prostate cancer treatment, management or care. The 
effect of technological change is found as a relative, not absolute, effect of medical 
advances specific to prostate cancer care. 
  The main report of the study is organized in three key chapters. Chapter 2 
presents the long run growth picture of spending. One year spending associated 
with prostate cancer care was calculated. The calculated spending shows how short 
term (one year) cancer care cost following the diagnosis of cancer changed over time. 
The calculated costs are in addition to average increase in the health care spending 
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of the general population. It is assumed that the calculated costs of cancer care 
reflect all specific changes related to prostate cancer, i.e. technological change.   
Chapter 3 uses outcome as a single measure of technological change. Prostate 
cancer caused death rate is used as the key outcome in this regard. Two 
assumptions are made in order to use particular study designs. The first 
assumption is that change in cost is „caused‟ by changes in cancer care resulting 
from technological change. The second assumption is that in health care spending 
and cancer care technologies are endogenous to each other and therefore they are 
simultaneously determined.  
Unlike Chapter 2, this chapter includes the calculation of the increase in 
health care spending with a denominator. So the chapter is a first step towards the 
cost-benefit or cost-effectiveness analysis of the technological change in prostate 
cancer care. However, cost-effectiveness or cost-benefit analysis is not the purpose 
of this study.     
 The last key chapter is Chapter 4, which is about measuring cost of specific 
technologies. The chapter has two objectives. First, it aims to measure how much 
the cancer care expenditure changed owing to these specific technologies. Second, 
how did the expenditure associated with new technologies behave over time? In 
other words, the specific interest was in the intercept and slope of the cancer care 
cost attributable to the specific cutting edge technologies in cancer care. The 
technologies included are three dimensional conformal radiation therapy (3D-CRT) 
and intensity modulated radiation therapy (IMRT).  
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5.2 Major findings and conclusions  
 All estimated costs are in 2005 dollars and costs, measured by expenditure or 
spending are all related to prostate cancer care, management or treatment. The 
average first year incremental spending following an individual‟s diagnosis of 
prostate cancer was $31,000 in 199328. It increased to $66,000 in 2002. The total net 
increase in expenditure in 10 years‟ period more than doubled (i.e. 113% increase). 
The trend of expenditure for the diagnosed population was increasing throughout 
the period.  
 The increase in expenditure associated with the diagnosis and treatment was 
from $48,018 to $85,267 during the same period. The increases in treatment related 
expenses were more than that of diagnosis related expenses in absolute amounts. 
But the growth rate of treatment related expenses during 10 years‟ time was lower, 
i.e. 80 percent, compared to 113 percent for diagnosis related expenses.  
 Growth of expenditures by treatment type was also estimated for three 
treatment groups: radical prostatectomy, radiation therapy and watchful waiting. 
Different trends of treatment expenses were observed for these three groups. For 
those who receive neither surgery nor radiation treatment, expenditures grew 
slightly in the beginning and after a period of stability, started growing again. For 
the radiation group, the expenses actually decreased during the first half of the 
study period before they started rising again. The growth of expenses for the 
surgery group is totally different. Treatment related expenditure for this group 
                                               
28
 The effect was not significant for 1992 and estimate is not available for 1991 due to the design of 
variable calculation. Data are available from 1991 and since the study design includes pre-diagnosis 
expenditure cases diagnosed in 1991 simply dropped out as they had no pre-diagnosis information.  
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grew throughout the study period. This suggests substantial and rapid changes in 
treatment choices for those who receive surgery as their definitive treatment option.  
 The findings from Chapter 2 suggest a substantial increase in health care 
expenditure that is explained by the changes in prostate cancer care during the 
study period. If all changes are loosely defined as technological changes, then 
technological change in the first year of prostate cancer care alone contributed 
about 100 percent increase in expenditure in 10 years‟ period. There were more 
substantial changes in treatment options than in overall care. Among treatment 
options, surgery saw the highest and the fastest growth of spending.   
The next strategy was to estimate the growth of spending using an objective 
measure of technological change. In this case, technological change was measured 
by annual death rate caused by PCa as a proxy. So, the denominator of spending 
was a unit decline in death rate associated with prostate cancer. Estimates using 
single equation model range from $174 to $201, while using simultaneous model, 
the estimates range from $179 to $206 for a unit decline in the PCa caused death 
rates. These are the average amounts that cost per patient in a year following 
diagnosis if cancer related deaths were to decline by 1 per 100,000 elderly 
populations. Using a moderate estimate, it would add to $19,055 per patient in the 
population studied for the entire decline in death rate caused by prostate cancer. In 
other words, from 1993 to 2002, there was $19,055 increase in average expenditure 
which can be attributed to decline in PCa caused death rate from 277 to 173 per 
100,000 individuals.  
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Interest also lies in what the cost is for one PCa death avoided. Using the 
same estimate as above, avoiding one prostate cancer related death in the 65 and 
older age group would cost $185,000 in the first year of care only.    
Finally, estimates of cost and its growth were made for two important 
innovations in radiation therapy to treat prostate cancer. Estimates show that one 
year average cost were $8,627 and $11,836 higher than SRT for 3D-CRT and 3D-
CRT and IMRT combined respectively. Similarly, two year cost differentials were 
$12,242 and $14,724 higher for 3D-CRT and 3D-CRT and IMRT combined 
respectively.  
Year by year estimates for the two technologies were also calculated in order 
to examine the growth trends. Estimates for 3D-CRT showed that expenditures for 
the treatment grew before it started falling showing an inverted U-shaped trend for 
both one year and two year expenses. However, if IMRT treatment group were also 
included, the expenditure associated with the choice of new treatments as opposed 
to conventional radiation treatment kept growing throughout the study period.  
The conclusion from this chapter is that new innovations in radiation therapy 
not only increased the cost of treatment, they also caused the rate of increase to 
grow. This suggests that the health care market structure is such that new 
technologies serve somehow as the instruments to enhance the market power of the 
health care providers.    
The behavior of spending over time supports different hypotheses about how 
new technologies enter the health care cost and expenditure functions. This 
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suggests that cost plays an important role on acceptability of a new technology that 
does not substantially improve outcomes. As acceptance rate grows later in the 
period, the incremental spending grows as well. The role of new technologies to 
drive up cost and spending, therefore, at least partly depends on the technology 
adoption behavior of the health care providers, such as who adopts the new 
technology first.  
This study is an attempt to measure the effect of technological change in 
health care spending and cost in the United States. This is an important area of 
research, but still there is a lack of studies focusing on the issue. Within its own 
limitations this study makes important contributions to this field of knowledge.  
 The conclusions from this study are drawn only from the information of a 
specific segment of the general population. Prostate cancer is, however, a major 
condition affecting elderly males and it has been given a high focus in care and 
management. The methods used are expected to apply to any similar conditions 
including all types of cancer.  
 In this research, disease specific health care costs are calculated as the 
marginal price of better care resulting from technological change. This type of 
research design and technique can be extended to other disease conditions to study 
the relative increase in health care resources devoted to provide care for those 
conditions.  
 A significant increase in health care expenditure in prostate cancer care may 
or may not be worth it for the gain made in outcomes. These findings may be used 
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to analyze the cost and benefits of technological change, which is not within the 
scope of this study.  
  Findings from technology specific study show that new technology may cause 
the cost not only to go up but also to increase over time. This suggests that new 
technologies are not only costly, they may cause the cost to grow even further 
because of the way new technologies are adopted and utilized.    
 The major limitation of this study is the study population. The findings are 
not applicable to the general population. Another limitation is it does not include 
prescription drug expenses, which make a significant component of total health care 
expenditure.  
 
5.3 Direction for future research  
The issues encountered and conclusions made in this study give rise to 
further research in this area. The important is finding an objective measure or an 
index of the use of health care technology. A way to measure the amount of 
technology used in care will provide a reliable and absolute estimate of the effect of 
technological change in health care spending.  
 Findings from this study can be used to measure the cost benefit or cost 
effectiveness of technological change in prostate cancer care. The estimated cost 
increases may be expressed in terms of a more common denominator such as quality 
adjusted life years (QUALYs). There may be better proxy measures of technological 
122 
 
 
change other than death rate. Using those measures will provide an interesting 
comparison to the findings from this study.  
 Since technology is an important contributor to overall health care spending 
and cost, the geographic variation in the use of latest innovations may also be 
exploited in order to estimate the effect of technology. The research question in this 
regard can be: If technology is a driver of spending, then to what extent does 
geographic variation in technology adoption explain geographic variation in 
spending?  
Study of health care technology markets will be a very good extension to this 
study. The findings from this research suggest that technology adoption behavior of 
hospitals and speed of technology diffusion may have important implications for the 
increase in cost due to new technologies. The way health care market is organized 
and the speed by which a new treatment is expanded are essentially linked with 
that.  Further research in this perspective will be crucial and have important policy 
implications.    
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APPENDIX A 
Table A1. Full equation estimates of cancer related spending by 
year of diagnosis (Table 2.2 Estimates by diagnosis status) 
Right Hand Side Variables Coef. 
Std. 
Err. 
P>z 
Expontiated Linear 
Prediction 
 Year*Diagnosis = 1     
    1992 0.740 1.015 0.466 $12,301 
    1993 1.343 0.041 0.000 $31,137 
    1994 1.398 0.034 0.000 $33,179 
    1995 1.415 0.035 0.000 $33,995 
    1996 1.504 0.036 0.000 $38,161 
    1997 1.578 0.035 0.000 $41,862 
    1998 1.676 0.037 0.000 $47,282 
    1999 1.762 0.035 0.000 $52,228 
    2000 1.755 0.026 0.000 $50,209 
    2001 1.880 0.025 0.000 $57,945 
    2002 2.002 0.025 0.000 $66,434 
Age 0.001 0.001 0.391 $9 
Charlson Comorbidity Score 0.189 0.003 0.000 $2,115 
Race—Black  -0.089 0.019 0.000 -$963 
Race—Other  -0.174 0.022 0.000 -$1,815 
Tumor Characteristics      
    Multi-site  -0.056 0.118 0.634 -$628 
    Metastatic 0.057 0.026 0.032 $652 
    Unstaged  -0.040 0.021 0.060 -$441 
Metro resident  -0.024 0.016 0.138 -$268 
Therapy started 0.105 0.013 0.000 $1,145 
% with College degree by Zip Code  0.001 0.001 0.210 $7 
Mean income by Zip Code 0.000 0.000 0.044 $0 
SEER Locations (Connecticut=0)      
    Detroit 0.116 0.024 0.000 $1,359 
    Hawaii -0.007 0.043 0.874 -$76 
    Iowa -0.344 0.024 0.000 -$3,391 
    New Mexico -0.226 0.034 0.000 -$2,288 
    Seattle -0.254 0.026 0.000 -$2,564 
    Utah -0.287 0.030 0.000 -$2,833 
    Atlanta Metro -0.047 0.033 0.163 -$512 
    Rural Georgia -0.121 0.085 0.155 -$1,284 
    Kentucky 0.086 0.032 0.007 $1,001 
    Louisiana 0.246 0.033 0.000 $3,111 
    New Jersey 0.483 0.026 0.000 $6,676 
    California 0.374 0.021 0.000 $4,608 
    Constant  8.359 0.141 0.000  
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Table A2. Full equation estimates of cancer related spending by 
year of diagnosis (Table 2.2 Estimates by diagnosis and 
treatment status) 
Right Hand Side Variables Coef. Std. Err. P>z 
Expontiated Linear 
Prediction in $ 
 Year*Diagnosis = 1     
    1992 
0.54 1.184 0.46 8,960 
    1993 
1.59 0.049 32.67 48,018 
    1994 
1.66 0.040 41.16 51,658 
    1995 
1.64 0.041 39.65 51,040 
    1996 
1.71 0.042 40.25 55,188 
    1997 
1.77 0.041 42.67 59,018 
    1998 
1.85 0.043 43.21 65,625 
    1999 
1.93 0.041 47.37 71,184 
    2000 
1.90 0.030 64.01 67,027 
    2001 
2.00 0.030 67.40 74,770 
    2002 
2.12 0.030 71.60 85,267 
Age 
0.00 0.001 2.95 40 
Charlson Comorbidity Score 
0.20 0.003 69.69 2471 
Race—Black  
-0.09 0.021 -4.24 -1056 
Race—Other  
-0.19 0.024 -7.71 -2184 
Tumor Characteristics     
     Multi-site  
-0.05 0.122 -0.43 -654 
    Metastatic 
0.05 0.031 1.78 700 
    Unstaged  
-0.02 0.025 -0.94 -295 
Metro resident  
-0.01 0.017 -0.71 -154 
Therapy started 
0.02 0.016 1.07 213 
% with College degree by Zip Code  
0.00 0.001 1.11 8 
Mean income by Zip Code 
0.00 0.000 -1.64 0 
SEER Locations (Connecticut=0)  
        Detroit 
0.11 0.026 4.44 1494 
    Hawaii 
0.01 0.046 0.13 74 
    Iowa 
-0.31 0.026 -12.06 -3503 
    New Mexico 
-0.20 0.037 -5.51 -2321 
    Seattle 
-0.24 0.027 -8.88 -2768 
    Utah 
-0.26 0.032 -8.02 -2911 
    Atlanta Metro 
-0.05 0.036 -1.47 -644 
    Rural Georgia 
-0.10 0.095 -1.01 -1147 
    Kentucky 
0.03 0.034 1.02 446 
    Louisiana 
0.20 0.037 5.54 2798 
    New Jersey 
0.39 0.028 14.20 5823 
    California 
0.37 0.023 16.45 5121 
    Constant  
8.38 0.149 56.41 
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APPENDIX B 
 
Table B1. Full equation results from the single equation model 
(Table 3.2 First year outcome as the variable of interest) 
Variables Coef. 
Std. 
Err. z P>z 
[95% Confidence 
Interval] 
Outcome--Year 1 -0.006 0.000 
-
38.200 0.000 -0.006 -0.006 
Therapy started 0.713 0.012 61.080 0.000 0.690 0.735 
Age -0.017 0.001 
-
20.190 0.000 -0.018 -0.015 
Charlson Score 0.044 0.002 19.940 0.000 0.040 0.049 
Race-Black -0.008 0.016 -0.520 0.602 -0.040 0.023 
Race--Other -0.015 0.019 -0.800 0.425 -0.053 0.022 
Multisite PCa presentation 0.285 0.142 2.010 0.044 0.007 0.563 
Metastatic PCa presentation 0.029 0.023 1.270 0.203 -0.016 0.074 
Unstaged PCa presentation -0.039 0.018 -2.220 0.026 -0.074 -0.005 
Metro resident 0.104 0.014 7.370 0.000 0.076 0.132 
% with college degree by Zip Code 0.001 0.000 1.460 0.144 0.000 0.001 
Mean income by Zip Code 
0.000 0.000 -1.640 0.100 0.000 0.000 
    Detroit 
0.059 0.021 2.860 0.004 0.019 0.099 
    Hawaii 
0.012 0.036 0.330 0.742 -0.059 0.082 
    Iowa 
-0.415 0.020 
-
20.500 0.000 -0.454 -0.375 
    New Mexico 
-0.229 0.028 -8.150 0.000 -0.284 -0.174 
    Seattle 
-0.445 0.022 
-
20.520 0.000 -0.487 -0.402 
    Utah 
-0.552 0.025 
-
22.030 0.000 -0.601 -0.502 
    Atlanta Metro 
-0.167 0.028 -5.950 0.000 -0.222 -0.112 
    Rural Georgia 
-0.133 0.076 -1.750 0.080 -0.281 0.016 
    Kentucky 
-0.222 0.029 -7.610 0.000 -0.280 -0.165 
    Louisiana 
-0.256 0.031 -8.390 0.000 -0.316 -0.196 
    New Jersey 
0.166 0.024 7.020 0.000 0.120 0.213 
    California 
0.012 0.018 0.640 0.522 -0.024 0.047 
Constant  
12.259 0.162 75.550 0.000 11.941 12.577 
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Table B2. Full equation results from the single equation model 
(Table 3.2 Second year outcome as the variable of interest) 
Variables Coef. 
Std. 
Err. z P>z 
[95% Confidence 
Interval] 
Outcome--Year 2 -0.006 0.000 -38.200 0.000 -0.006 -0.006 
Therapy started 0.713 0.012 61.080 0.000 0.690 0.735 
Age -0.017 0.001 -20.190 0.000 -0.018 -0.015 
Charlson Score 0.044 0.002 19.940 0.000 0.040 0.049 
Race-Black -0.008 0.016 -0.520 0.602 -0.040 0.023 
Race--Other -0.015 0.019 -0.800 0.425 -0.053 0.022 
Multisite PCa presentation 0.285 0.142 2.010 0.044 0.007 0.563 
Metastatic PCa 
presentation 0.029 0.023 1.270 0.203 -0.016 0.074 
Unstaged PCa 
presentation -0.039 0.018 -2.220 0.026 -0.074 -0.005 
Metro resident 0.104 0.014 7.370 0.000 0.076 0.132 
% with college degree by 
Zip Code 0.001 0.000 1.460 0.144 0.000 0.001 
Mean income by Zip Code 
0.000 0.000 -1.640 0.100 0.000 0.000 
    Detroit 
0.059 0.021 2.860 0.004 0.019 0.099 
    Hawaii 
0.012 0.036 0.330 0.742 -0.059 0.082 
    Iowa 
-0.415 0.020 -20.500 0.000 -0.454 -0.375 
    New Mexico 
-0.229 0.028 -8.150 0.000 -0.284 -0.174 
    Seattle 
-0.445 0.022 -20.520 0.000 -0.487 -0.402 
    Utah 
-0.552 0.025 -22.030 0.000 -0.601 -0.502 
    Atlanta Metro 
-0.167 0.028 -5.950 0.000 -0.222 -0.112 
    Rural Georgia 
-0.133 0.076 -1.750 0.080 -0.281 0.016 
    Kentucky 
-0.222 0.029 -7.610 0.000 -0.280 -0.165 
    Louisiana 
-0.256 0.031 -8.390 0.000 -0.316 -0.196 
    New Jersey 
0.166 0.024 7.020 0.000 0.120 0.213 
    California 
0.012 0.018 0.640 0.522 -0.024 0.047 
Constant  
12.259 0.162 75.550 0.000 11.941 12.577 
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Table B3. Full equation results from the single equation model 
(Table 3.2 Third year outcome as the variable of interest) 
Variables Coef. 
Std. 
Err. z P>z 
[95% Confidence 
Interval] 
Outcome--Year 3 -0.006 0.000 -38.200 0.000 -0.006 -0.006 
Therapy started 0.713 0.012 61.080 0.000 0.690 0.735 
Age -0.017 0.001 -20.190 0.000 -0.018 -0.015 
Charlson Score 0.044 0.002 19.940 0.000 0.040 0.049 
Race-Black -0.008 0.016 -0.520 0.602 -0.040 0.023 
Race--Other -0.015 0.019 -0.800 0.425 -0.053 0.022 
Multisite PCa presentation 0.285 0.142 2.010 0.044 0.007 0.563 
Metastatic PCa 
presentation 0.029 0.023 1.270 0.203 -0.016 0.074 
Unstaged PCa 
presentation -0.039 0.018 -2.220 0.026 -0.074 -0.005 
Metro resident 0.104 0.014 7.370 0.000 0.076 0.132 
% with college degree by 
Zip Code 0.001 0.000 1.460 0.144 0.000 0.001 
Mean income by Zip Code 
0.000 0.000 -1.640 0.100 0.000 0.000 
    Detroit 
0.059 0.021 2.860 0.004 0.019 0.099 
    Hawaii 
0.012 0.036 0.330 0.742 -0.059 0.082 
    Iowa 
-0.415 0.020 -20.500 0.000 -0.454 -0.375 
    New Mexico 
-0.229 0.028 -8.150 0.000 -0.284 -0.174 
    Seattle 
-0.445 0.022 -20.520 0.000 -0.487 -0.402 
    Utah 
-0.552 0.025 -22.030 0.000 -0.601 -0.502 
    Atlanta Metro 
-0.167 0.028 -5.950 0.000 -0.222 -0.112 
    Rural Georgia 
-0.133 0.076 -1.750 0.080 -0.281 0.016 
    Kentucky 
-0.222 0.029 -7.610 0.000 -0.280 -0.165 
    Louisiana 
-0.256 0.031 -8.390 0.000 -0.316 -0.196 
    New Jersey 
0.166 0.024 7.020 0.000 0.120 0.213 
    California 
0.012 0.018 0.640 0.522 -0.024 0.047 
Constant  
12.259 0.162 75.550 0.000 11.941 12.577 
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Table B4. Full equation results from the single equation model 
(Table 3.2 Fourth year outcome as the variable of interest) 
Variables Coef. 
Std. 
Err. z P>z 
[95% Confidence 
Interval] 
Outcome--Year 4 -0.006 0.000 -38.200 0.000 -0.006 -0.006 
Therapy started 0.713 0.012 61.080 0.000 0.690 0.735 
Age -0.017 0.001 -20.190 0.000 -0.018 -0.015 
Charlson Score 0.044 0.002 19.940 0.000 0.040 0.049 
Race-Black -0.008 0.016 -0.520 0.602 -0.040 0.023 
Race--Other -0.015 0.019 -0.800 0.425 -0.053 0.022 
Multisite PCa presentation 0.285 0.142 2.010 0.044 0.007 0.563 
Metastatic PCa 
presentation 0.029 0.023 1.270 0.203 -0.016 0.074 
Unstaged PCa 
presentation -0.039 0.018 -2.220 0.026 -0.074 -0.005 
Metro resident 0.104 0.014 7.370 0.000 0.076 0.132 
% with college degree by 
Zip Code 0.001 0.000 1.460 0.144 0.000 0.001 
Mean income by Zip Code 
0.000 0.000 -1.640 0.100 0.000 0.000 
    Detroit 
0.059 0.021 2.860 0.004 0.019 0.099 
    Hawaii 
0.012 0.036 0.330 0.742 -0.059 0.082 
    Iowa 
-0.415 0.020 -20.500 0.000 -0.454 -0.375 
    New Mexico 
-0.229 0.028 -8.150 0.000 -0.284 -0.174 
    Seattle 
-0.445 0.022 -20.520 0.000 -0.487 -0.402 
    Utah 
-0.552 0.025 -22.030 0.000 -0.601 -0.502 
    Atlanta Metro 
-0.167 0.028 -5.950 0.000 -0.222 -0.112 
    Rural Georgia 
-0.133 0.076 -1.750 0.080 -0.281 0.016 
    Kentucky 
-0.222 0.029 -7.610 0.000 -0.280 -0.165 
    Louisiana 
-0.256 0.031 -8.390 0.000 -0.316 -0.196 
    New Jersey 
0.166 0.024 7.020 0.000 0.120 0.213 
    California 
0.012 0.018 0.640 0.522 -0.024 0.047 
Constant  
12.259 0.162 75.550 0.000 11.941 12.577 
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Table B5. Full equation results from the single equation model 
(Table 3.2 Fifth year outcome as the variable of interest) 
Variables Coef. 
Std. 
Err. z P>z 
[95% Confidence 
Interval] 
Outcome--Year 5 -0.006 0.000 -38.200 0.000 -0.006 -0.006 
Therapy started 0.713 0.012 61.080 0.000 0.690 0.735 
Age -0.017 0.001 -20.190 0.000 -0.018 -0.015 
Charlson Score 0.044 0.002 19.940 0.000 0.040 0.049 
Race-Black -0.008 0.016 -0.520 0.602 -0.040 0.023 
Race--Other -0.015 0.019 -0.800 0.425 -0.053 0.022 
Multisite PCa presentation 0.285 0.142 2.010 0.044 0.007 0.563 
Metastatic PCa 
presentation 0.029 0.023 1.270 0.203 -0.016 0.074 
Unstaged PCa 
presentation -0.039 0.018 -2.220 0.026 -0.074 -0.005 
Metro resident 0.104 0.014 7.370 0.000 0.076 0.132 
% with college degree by 
Zip Code 0.001 0.000 1.460 0.144 0.000 0.001 
Mean income by Zip Code 
0.000 0.000 -1.640 0.100 0.000 0.000 
    Detroit 
0.059 0.021 2.860 0.004 0.019 0.099 
    Hawaii 
0.012 0.036 0.330 0.742 -0.059 0.082 
    Iowa 
-0.415 0.020 -20.500 0.000 -0.454 -0.375 
    New Mexico 
-0.229 0.028 -8.150 0.000 -0.284 -0.174 
    Seattle 
-0.445 0.022 -20.520 0.000 -0.487 -0.402 
    Utah 
-0.552 0.025 -22.030 0.000 -0.601 -0.502 
    Atlanta Metro 
-0.167 0.028 -5.950 0.000 -0.222 -0.112 
    Rural Georgia 
-0.133 0.076 -1.750 0.080 -0.281 0.016 
    Kentucky 
-0.222 0.029 -7.610 0.000 -0.280 -0.165 
    Louisiana 
-0.256 0.031 -8.390 0.000 -0.316 -0.196 
    New Jersey 
0.166 0.024 7.020 0.000 0.120 0.213 
    California 
0.012 0.018 0.640 0.522 -0.024 0.047 
Constant  
12.259 0.162 75.550 0.000 11.941 12.577 
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Table B6. Full equation results from the single equation model 
(Table 3.2 Average of first to fifth year outcome as the variable of interest) 
Variables Coef. 
Std. 
Err. z P>z 
[95% Confidence 
Interval] 
Outcome—Average of Year 1-5 -0.006 0.000 -38.200 0.000 -0.006 -0.006 
Therapy started 0.713 0.012 61.080 0.000 0.690 0.735 
Age -0.017 0.001 -20.190 0.000 -0.018 -0.015 
Charlson Score 0.044 0.002 19.940 0.000 0.040 0.049 
Race-Black -0.008 0.016 -0.520 0.602 -0.040 0.023 
Race--Other -0.015 0.019 -0.800 0.425 -0.053 0.022 
Multisite PCa presentation 0.285 0.142 2.010 0.044 0.007 0.563 
Metastatic PCa presentation 0.029 0.023 1.270 0.203 -0.016 0.074 
Unstaged PCa presentation -0.039 0.018 -2.220 0.026 -0.074 -0.005 
Metro resident 0.104 0.014 7.370 0.000 0.076 0.132 
% with college degree by Zip 
Code 0.001 0.000 1.460 0.144 0.000 0.001 
Mean income by Zip Code 
0.000 0.000 -1.640 0.100 0.000 0.000 
    Detroit 
0.059 0.021 2.860 0.004 0.019 0.099 
    Hawaii 
0.012 0.036 0.330 0.742 -0.059 0.082 
    Iowa 
-0.415 0.020 -20.500 0.000 -0.454 -0.375 
    New Mexico 
-0.229 0.028 -8.150 0.000 -0.284 -0.174 
    Seattle 
-0.445 0.022 -20.520 0.000 -0.487 -0.402 
    Utah 
-0.552 0.025 -22.030 0.000 -0.601 -0.502 
    Atlanta Metro 
-0.167 0.028 -5.950 0.000 -0.222 -0.112 
    Rural Georgia 
-0.133 0.076 -1.750 0.080 -0.281 0.016 
    Kentucky 
-0.222 0.029 -7.610 0.000 -0.280 -0.165 
    Louisiana 
-0.256 0.031 -8.390 0.000 -0.316 -0.196 
    New Jersey 
0.166 0.024 7.020 0.000 0.120 0.213 
    California 
0.012 0.018 0.640 0.522 -0.024 0.047 
Constant  
12.259 0.162 75.550 0.000 11.941 12.577 
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Table B7. Full equation results from the simultaneous equation model 
(Table 3.3 Average of first year outcome as the variable of interest) 
 
Equation 1 
Dependent 
variable=Expenditure 
Equation 2 
Dependent 
variable=Outcome year 1 
  Coef. Std. Err. P>z Coef. 
Std. 
Err. P>z 
Outcome—Year 1 -206 5.37 0.000 
  
  
Therapy started 19959 391.71 0.000 
  
  
Age -483 27.36 0.000 0.000 0.000 0.014 
Charlson Score 1537 75.60 0.000 0.000 0.000 0.605 
Race-Black 416 543.67 0.445 0.000 0.001 0.571 
Race--Other 103 650.87 0.874 -0.002 0.001 0.126 
Multisite Pca presentation 14453 3561.81 0.000 0.000 0.005 0.970 
Metastatic Pca presentation 425 778.05 0.585 -0.002 0.001 0.039 
Unstaged Pca presentation -858 596.46 0.151 -0.001 0.001 0.107 
Metro resident 3459 476.41 0.000 0.002 0.001 0.011 
% with college degree by Zip 
Code 42 14.81 0.005 0.000 0.000 0.551 
Mean income by Zip Code 
0 0.012 0.004 0.000 0.000 0.677 
    Detroit 3512 682.74 0.000 0.001 0.001 0.545 
    Hawaii 806 1224.72 0.510 0.006 0.002 0.003 
    Iowa -11530 689.29 0.000 0.003 0.001 0.004 
    New Mexico -6654 957.40 0.000 0.007 0.001 0.000 
    Seattle 
-12389 725.13 0.000 0.004 0.001 0.001 
    Utah -13252 851.35 0.000 0.003 0.001 0.022 
    Atlanta Metro -4976 943.72 0.000 0.000 0.001 0.917 
    Rural Georgia -4571 2575.33 0.076 -0.005 0.004 0.169 
    Kentucky -8461 988.50 0.000 0.004 0.002 0.017 
    Louisiana -9242 1036.92 0.000 0.004 0.002 0.024 
    New Jersey 10040 796.75 0.000 0.000 0.001 0.780 
    California 2202 601.64 0.000 0.002 0.001 0.018 
Expenditure in '000   
 
  0.001 0.000 0.016 
Year of Diagnosis =1   
 
  
  
  
    Year 93   
 
  1.795 0.001 0.000 
    Year 94   
 
  -4.205 0.001 0.000 
    Year 95   
 
  -13.455 0.001 0.000 
    Year 96   
 
  -23.075 0.001 0.000 
    Year 97   
 
  -36.425 0.001 0.000 
    Year 98   
 
  -48.196 0.001 0.000 
    Year 99   
 
  -55.206 0.001 0.000 
    Year 00   
 
  -64.556 0.001 0.000 
    Year 01   
 
  -73.306 0.001 0.000 
    Year 02   
 
  -81.016 0.001 0.000 
Constant  90495 4403.312 0.000 290.671 0.007 0.000 
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Table B8. Full equation results from the simultaneous equation model 
(Table 3.3 Average of second year outcome as the variable of interest) 
 
Equation 1 
Dependent Variable=Expenditure 
Equation 2 
Dependent Variable=Outcome year 1 
  Coef. Std. Err. P>z Coef. Std. Err. P>z 
Outcome—Year 2 -186 4.95 0.000 
   Therapy started 20029 391.98 0.000 
   Age -478 27.37 0.000 -0.0004 0.0002 0.015 
Charlson Score 1525 75.61 0.000 0.000 0.001 0.612 
Race-Black 377 543.83 0.489 0.002 0.003 0.573 
Race--Other 33 651.12 0.960 0.006 0.004 0.127 
Multisite Pca presentation 14436 3562.73 0.000 0.001 0.021 0.970 
Metastatic Pca presentation 398 778.26 0.609 0.009 0.004 0.040 
Unstaged Pca presentation -856 596.97 0.152 0.006 0.003 0.107 
Metro resident 3377 476.41 0.000 -0.007 0.003 0.011 
% with college degree by Zip Code 42 14.81 0.005 0.000 0.000 0.550 
Mean income by Zip Code 
0 0.012 0.004 0.000 0.000 0.676 
    Detroit 
3601 682.82 0.000 -0.002 0.004 0.548 
    Hawaii 844 1225.06 0.491 -0.021 0.007 0.003 
    Iowa -11560 689.46 0.000 -0.012 0.004 0.004 
    New Mexico -6657 957.65 0.000 -0.027 0.006 0.000 
    Seattle 
-12323 725.27 0.000 -0.015 0.004 0.001 
    Utah -13215 851.57 0.000 -0.012 0.005 0.022 
    Atlanta Metro -4940 943.96 0.000 0.001 0.005 0.915 
    Rural Georgia 
-4636 2576.01 0.072 0.020 0.015 0.169 
    Kentucky 
-8001 987.04 0.000 -0.014 0.006 0.018 
    Louisiana -8811 1035.73 0.000 -0.014 0.006 0.025 
    New Jersey 10553 794.25 0.000 -0.001 0.005 0.798 
    California 2391 601.35 0.000 -0.008 0.004 0.019 
Expenditure in '000 
   
-0.003 0.001 0.016 
Year of Diagnosis =1 
          Year 93 
   
-5.602 0.004 0.000 
    Year 94 
   
-14.852 0.004 0.000 
    Year 95 
   
-24.471 0.004 0.000 
    Year 96 
   
-37.820 0.004 0.000 
    Year 97 
   
-49.589 0.004 0.000 
    Year 98 
   
-56.598 0.004 0.000 
    Year 99 
   
-65.948 0.004 0.000 
    Year 00 
   
-74.697 0.004 0.000 
    Year 01 
   
-82.406 0.004 0.000 
    Year 02 
   
-95.076 0.004 0.000 
Constant  83565 4357.18 0.000 292.135 0.025 0.000 
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Table B9. Full equation results from the simultaneous equation model 
(Table 3.3 Third year outcome as the variable of interest) 
 
Equation 1 
Dependent Variable=Expenditure 
Equation 2 
Dependent Variable=Outcome year 1 
  Coef. Std. Err. P>z Coef. Std. Err. P>z 
Outcome—Year 3 -179 4.8 0.00 
   Therapy started 20053 392.1 0.000 
   Age -476 27.4 0.000 0.001 0.001 0.015 
Charlson Score 1516 75.6 0.000 -0.001 0.002 0.613 
Race-Black 361 543.9 0.507 -0.006 0.010 0.573 
Race--Other 5 651.3 0.994 -0.018 0.012 0.127 
Multisite Pca presentation 14443 3563.3 0.000 -0.002 0.065 0.970 
Metastatic Pca presentation 376 778.4 0.629 -0.029 0.014 0.040 
Unstaged Pca presentation -869 597.2 0.146 -0.017 0.011 0.108 
Metro resident 3349 476.5 0.000 0.022 0.009 0.011 
% with college degree by Zip Code 41 14.8 0.005 0.000 0.000 0.550 
Mean income by Zip Code 
0 0.0 0.004 0.000 0.000 0.677 
    Detroit 
3658 682.9 0.000 0.008 0.013 0.549 
    Hawaii 887 1225.3 0.469 0.066 0.022 0.003 
    Iowa -11560 689.6 0.000 0.038 0.013 0.004 
    New Mexico -6611 957.8 0.000 0.085 0.018 0.000 
    Seattle 
-12270 725.3 0.000 0.047 0.014 0.001 
    Utah -13177 851.7 0.000 0.037 0.016 0.022 
    Atlanta Metro -4923 944.1 0.000 -0.002 0.017 0.915 
    Rural Georgia 
-4676 2576.4 0.070 -0.064 0.047 0.169 
    Kentucky 
-7772 986.5 0.000 0.044 0.018 0.018 
    Louisiana -8579 1035.2 0.000 0.043 0.019 0.025 
    New Jersey 10797 793.3 0.000 0.004 0.016 0.798 
    California 2497 601.2 0.000 0.027 0.011 0.019 
Expenditure in '000 
   
0.009 0.004 0.016 
Year of Diagnosis =1 
          Year 93 
   
-10.508 0.012 0.000 
    Year 94 
   
-20.128 0.012 0.000 
    Year 95 
   
-33.480 0.013 0.000 
    Year 96 
   
-45.253 0.013 0.000 
    Year 97 
   
-52.265 0.013 0.000 
    Year 98 
   
-61.618 0.013 0.000 
    Year 99 
   
-70.370 0.013 0.000 
    Year 00 
   
-78.081 0.012 0.000 
    Year 01 
   
-90.755 0.013 0.000 
    Year 02 
   
-98.557 0.013 0.000 
Constant  80060 4336.1 0.000 287.569 0.079 0.000 
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Table B10. Full equation results from the simultaneous equation model 
(Table 3.3 Fourth year outcome as the variable of interest) 
 
Equation 1 
Dependent Variable=Expenditure 
Equation 2 
Dependent Variable=Outcome year 5 
  Coef. Std. Err. P>z Coef. Std. Err. P>z 
Outcome—Year 4 -180 4.93 0.000 
   Therapy started 20061 392.26 0.000 
   Age -474 27.37 0.000 0.002 0.001 0.015 
Charlson Score 1506 75.61 0.000 -0.002 0.003 0.614 
Race-Black 369 544.04 0.497 -0.009 0.015 0.572 
Race--Other 6 651.43 0.993 -0.028 0.018 0.126 
Multisite Pca presentation 14430 3564.12 0.000 -0.004 0.100 0.970 
Metastatic Pca presentation 339 778.54 0.663 -0.045 0.022 0.040 
Unstaged Pca presentation -940 597.36 0.115 -0.027 0.017 0.109 
Metro resident 3332 476.65 0.000 0.034 0.013 0.011 
% with college degree by Zip Code 41 14.82 0.005 0.000 0.000 0.550 
Mean income by Zip Code 
0 0.012 0.004 0.000 0.000 0.677 
    Detroit 
3700 683.00 0.000 0.012 0.019 0.550 
    Hawaii 905 1225.58 0.460 0.102 0.034 0.003 
    Iowa -11544 689.73 0.000 0.058 0.020 0.004 
    New Mexico -6584 958.09 0.000 0.130 0.027 0.000 
    Seattle 
-12223 725.48 0.000 0.072 0.021 0.001 
    Utah -13144 851.90 0.000 0.057 0.025 0.022 
    Atlanta Metro -4890 944.33 0.000 -0.003 0.026 0.915 
    Rural Georgia 
-4645 2577.02 0.071 -0.099 0.072 0.169 
    Kentucky 
-7693 987.04 0.000 0.067 0.029 0.018 
    Louisiana -8458 1035.50 0.000 0.066 0.029 0.025 
    New Jersey 10905 793.98 0.000 0.006 0.024 0.798 
    California 2552 601.33 0.000 0.041 0.017 0.019 
Expenditure in '000 
   
0.013 0.005 0.016 
Year of Diagnosis =1 
          Year 93 
   
-11.560 0.018 0.000 
    Year 94 
   
-24.910 0.019 0.000 
    Year 95 
   
-36.683 0.020 0.000 
    Year 96 
   
-43.696 0.020 0.000 
    Year 97 
   
-53.051 0.020 0.000 
    Year 98 
   
-61.805 0.020 0.000 
    Year 99 
   
-69.518 0.020 0.000 
    Year 00 
   
-82.190 0.018 0.000 
    Year 01 
   
-89.996 0.019 0.000 
    Year 02 
   
-96.279 0.021 0.000 
Constant  78389 4330.54 0.000 278.909 0.122 0.000 
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Table B11. Full equation results from the simultaneous equation model 
(Table 3.3 Fifth year outcome as the variable of interest) 
 
Equation 1 
Dependent Variable=Expenditure 
Equation 2 
Dependent Variable=Outcome 
year 5 
  Coef. Std. Err. P>z Coef. 
Std. 
Err. P>z 
Outcome—Year 5 -185 5.07 0.000 
   Therapy started 20070 392.27 0.000 
   Age -474 27.37 0.000 0.002 0.001 0.015 
Charlson Score 1507 75.61 0.000 -0.002 0.003 0.614 
Race-Black 359 544.03 0.509 -0.009 0.016 0.573 
Race--Other -8 651.42 0.990 -0.029 0.019 0.127 
Multisite Pca presentation 14441 3564.0 0.000 -0.004 0.104 0.970 
Metastatic Pca presentation 340 778.52 0.662 -0.047 0.023 0.040 
Unstaged Pca presentation -982 597.11 0.100 -0.028 0.017 0.109 
Metro resident 3311 476.56 0.000 0.036 0.014 0.011 
% with college degree by Zip Code 41 14.82 0.005 0.000 0.000 0.550 
Mean income by Zip Code 
0 0.012 0.004 0.000 0.000 0.677 
    Detroit 
3696 682.98 0.000 0.012 0.020 0.549 
    Hawaii 883 1225.5 0.471 0.106 0.036 0.003 
    Iowa -11565 689.71 0.000 0.060 0.021 0.004 
    New Mexico -6604 958.05 0.000 0.136 0.028 0.000 
    Seattle 
-12224 725.46 0.000 0.075 0.022 0.001 
    Utah -13158 851.88 0.000 0.059 0.026 0.022 
    Atlanta Metro -4882 944.29 0.000 -0.003 0.027 0.914 
    Rural Georgia 
-4651 2577.0 0.071 -0.103 0.075 0.169 
    Kentucky 
-7610 986.44 0.000 0.070 0.030 0.018 
    Louisiana -8397 1035.1 0.000 0.068 0.031 0.025 
    New Jersey 10999 793.00 0.000 0.006 0.025 0.800 
    California 2575 601.22 0.000 0.043 0.018 0.019 
Expenditure in '000 
   
0.014 0.006 0.016 
Year of Diagnosis =1 
          Year 93 
   
-15.368 0.018 0.000 
    Year 94 
   
-27.138 0.020 0.000 
    Year 95 
   
-34.150 0.020 0.000 
    Year 96 
   
-43.504 0.021 0.000 
    Year 97 
   
-52.259 0.021 0.000 
    Year 98 
   
-59.973 0.021 0.000 
    Year 99 
   
-72.647 0.021 0.000 
    Year 00 
   
-80.449 0.019 0.000 
    Year 01 
   
-86.734 0.020 0.000 
    Year 02 
   
-96.098 0.022 0.000 
Constant  77841 4325.805 0.000 269.356 0.127 0.000 
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Table B12. Full equation results from the simultaneous equation model 
(Table 3.3 Average of first to fifth year outcome as the variable of interest) 
 
Equation 1 Dependent 
Variable=Expenditure 
Equation 2 Dependent 
Variable=Outcome average of 
year 1-5 
  Coef. Std. Err. P>z Coef. Std. Err. P>z 
Outcome—average of year 1-5 -188 5.04 0.000 
   
Therapy started 20044 392.06 0.000 
   
Age -477 27.37 0.000 0.001 0.000 0.015 
Charlson Score 1521 75.61 0.000 -0.001 0.002 0.612 
Race-Black 373 543.88 0.492 -0.004 0.008 0.573 
Race--Other 19 651.20 0.977 -0.014 0.009 0.127 
Multisite Pca presentation 14431 3563.1 0.000 -0.002 0.051 0.970 
Metastatic Pca presentation 386 778.32 0.620 -0.023 0.011 0.040 
Unstaged Pca presentation -872 597.07 0.144 -0.014 0.009 0.108 
Metro resident 3379 476.50 0.000 0.017 0.007 0.011 
% with college degree by Zip Code 42 14.81 0.005 0.000 0.000 0.550 
Mean income by Zip Code 
-0.04 0.012 0.004 0.000 0.000 0.677 
    Detroit 
3623 682.86 0.000 0.006 0.010 0.548 
    Hawaii 
874 1225.2 0.476 0.052 0.017 0.003 
    Iowa 
-11550 689.52 0.000 0.029 0.010 0.004 
    New Mexico 
-6614 957.77 0.000 0.066 0.014 0.000 
    Seattle 
-12291 725.31 0.000 0.037 0.011 0.001 
    Utah 
-13187 851.65 0.000 0.029 0.013 0.022 
    Atlanta Metro 
-4934 944.05 0.000 -0.001 0.013 0.915 
    Rural Georgia 
-4645 2576.2 0.071 -0.050 0.037 0.169 
    Kentucky 
-7954 987.19 0.000 0.034 0.014 0.018 
    Louisiana 
-8743 1035.8 0.000 0.033 0.015 0.025 
    New Jersey 
10603 794.46 0.000 0.003 0.012 0.793 
    California 
2428 601.35 0.000 0.021 0.009 0.019 
Expenditure in '000 
   
0.007 0.003 0.016 
Year of Diagnosis =1 
      
    Year 93 
   
-8.248 0.009 0.000 
    Year 94 
   
-18.246 0.010 0.000 
    Year 95 
   
-28.448 0.010 0.000 
    Year 96 
   
-38.670 0.010 0.000 
    Year 97 
   
-48.718 0.010 0.000 
    Year 98 
   
-57.638 0.010 0.000 
    Year 99 
   
-66.738 0.010 0.000 
    Year 00 
   
-75.995 0.009 0.000 
    Year 01 
   
-84.639 0.010 0.000 
    Year 02 
   
-93.405 0.011 0.000 
Constant  
82207 4349.785 0.000 283.728 0.062 0.000 
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Technological change has a major role in driving up health care cost and 
expenditure. Yet we are not fully able to know the extent to which technological 
change affects cost and expenditure and the way new technologies enter the cost or 
expenditure functions. This paper uses historical data of US elderly males to see 
how health care spending associated with prostate cancer treatment behaves over 
time. Understanding the extent and mechanism by which a new technology actually 
translates into higher cost are main objectives of this study.   
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Study design, data and organization of the report:  
This study uses a retrospective research design with observational historical 
data. The subjects are Medicare enrolled individuals aged 65 or above who were 
diagnosed with prostate cancer from 1991 to 2002. SEER Medicare-linked database 
is used in the study. In Chapter 2, I present a long run view of health care spending 
growth. Spending associated with prostate cancer care was calculated by diagnosis, 
diagnosis and treatment and method of treatment status. Chapter 3 uses outcome 
as a single measure of technological change. Prostate cancer caused death rate is 
used as the key outcome in this regard. The last key chapter is Chapter 4, which is 
focused on the two innovations in external beam radiation therapy. Of main interest 
is whether the incremental spending caused by new treatments grows over time. 
Two innovations in radiation therapy, 3D-CRT and IMRT, are examined.  
 Major findings and conclusions:  
The average first year incremental spending following an individual‟s 
diagnosis of prostate cancer increased from $31,000 in 1993 to $66,000 in 2002, 
which is 113%. The increase in expenditure associated with the diagnosis and 
treatment was from $48,018 to $85,267 (80%) during the same period. The findings 
suggest a substantial increase in health care expenditure that is explained by the 
changes in prostate cancer care during the study period. If all changes are loosely 
defined as technological changes, then technological change in the first year of 
prostate cancer care alone contributed about 100 percent increase in expenditure in 
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10 years‟ period. There were more substantial changes in treatment options than in 
overall care. Among treatment options, surgery saw the highest and the fastest 
growth of spending.  
The estimates using the death rate as a proxy measure of technological 
change show that the cost per patient would add to $19,055 for the entire decline in 
death rate caused by prostate cancer. It also meant avoiding one prostate cancer 
related death in the 65 and older age group would cost $185,000 in the first year of 
care only. The findings imply that avoiding a death from PCa gave about 7 
additional life years in the period. The first year cost of additional life year from this 
perspective is about $26,000.     
Finally, estimates show that one year average costs were $8,627 and $11,836 
higher than SRT for 3D-CRT and 3D-CRT and IMRT combined respectively. 
Similarly, two year cost differentials were $12,242 and $14,724 higher for 3D-CRT 
and 3D-CRT and IMRT combined respectively. The findings show that incremental 
spending of 3D-CRT rose consistently for a certain period before it started 
subsiding.  Estimates that included both 3D-CRT and IMRT show that incremental 
spending did not subside but kept increasing after IMRT was introduced. It is found 
that the incremental cost of new technology rises as the acceptance of that 
technology gains momentum. This suggests that technology also enters cost and 
expenditure functions through the strategic plans of health care providers, 
primarily hospitals. Therefore the role of new technologies to drive up cost and 
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spending at least partly depends on the technology adoption behavior of the health 
care providers, such as who adopts the new technology first.  
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